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Background   The apelin system is a novel peptidic pathway widely expressed in the 
heart and vasculature. In preclinical studies, apelin receptor agonism mediates 
nitric oxide-dependent vasodilatation, reduces ventricular preload and afterload and 
potently increases myocardial contractility. In preclinical models of heart failure, 
expression of the apelin pathway is down regulated but the haemodynamic effects of 
apelin receptor agonism are preserved. These changes in expression appear to be 
paralleled in patients with chronic heart failure but the cardiovascular actions of 
apelin in vivo in man are, to date, unknown. Detailed clinical investigation is 
therefore required to establish the role of apelin in human cardiovascular physiology 
and pathophysiology and to explore the therapeutic potential of apelin receptor 
agonism in patients with heart failure. 
 
Objectives   Through a series of in vivo clinical studies: 1) to establish the direct 
vascular actions of apelin in the peripheral venous, peripheral arterial and coronary 
arterial circulations; 2) to determine the contribution of the endothelium-derived 
vasodilators, nitric oxide and prostacyclin, to the vascular actions of apelin; 3) to 
establish the effects of apelin on cardiac contractility and systemic haemodynamics; 
4) to compare the direct vascular and systemic haemodynamic effects of the full-
length mature apelin peptide, apelin-36, with a shorter, biologically active carboxyl 
(C)-terminal fragment, (Pyr1)apelin-13); and 5) to establish whether the local 
vascular and systemic haemodynamic effects of apelin are altered in patients with 
chronic heart failure.  
 
Methods   The cardiovascular effects of apelin were assessed in 32 healthy 
volunteers, 6 patients undergoing elective diagnostic coronary angiography, 
18 patients with stable New York Heart Association (NYHA) class II-III chronic 
heart failure and 18 age- and sex-matched healthy controls. Dorsal hand vein tone 
was assessed by the Aellig hand vein technique during local intravenous               
infusions (0.1-3 nmol/min) of apelin-36, (Pyr1)apelin-13, and sodium nitroprusside 
(SNP; 0.6 nmol/min). Forearm blood flow was measured by venous occlusion 
plethysmography during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 
(0.01-30 nmol/min) and subsequently in the presence or absence of a ‘nitric oxide 
clamp’ (nitric oxide synthase inhibitor, L-NG-monomethylarginine (L-NMMA; 
8 µmol/min), co-infused with SNP (90-900 ng/min)), or a single oral dose of aspirin 
(600 mg) or matched placebo. Coronary blood flow was evaluated by quantitative 
coronary angiography (QCA) and Doppler flow wire, and left ventricular pressures 
measured by pressure wire before and after intracoronary injection of apelin-36 
(20 and 200 nM), 0.9% saline and glyceryl trinitrate (GTN) (100 µg). Blood 
pressure, heart rate, cardiac output and peripheral vascular resistance were assessed 
by sphygmomanometry and thoracic electrical bioimpedance (TEB) during systemic 
intravenous infusion of apelin-36 and (Pyr1)apelin-13 (30-300 nmol/min). Forearm 
blood flow and systemic haemodynamic responses to (Pyr1)apelin-13 in patients with 
chronic heart failure were then compared with age- and sex-matched healthy 
controls. 
 
Results   Although SNP caused venodilatation (P<0.0001), apelin-36 and 
(Pyr1)apelin-13 had no effect on dorsal hand vein diameter (P=0.2). Both apelin 
isoforms caused vasodilatation in forearm resistance vessels (P<0.0001) but the 
offset was slower with apelin-36. (Pyr1)apelin-13-mediated vasodilatation was 
attenuated by the nitric oxide clamp (P=0.004) but unaffected by aspirin (P=0.7). 
Intracoronary bolus of apelin-36 increased coronary blood flow and the maximum 
rate of rise in left ventricular pressure, and reduced peak and end-diastolic left 
ventricular pressures (all P<0.05). Both (Pyr1)apelin-13 and apelin-36 increased 
heart rate and cardiac output whilst reducing peripheral vascular resistance (P<0.01 
for all) with no overall effect on blood pressure. Intrabrachial infusions of 
(Pyr1)apelin-13, acetylcholine and SNP caused forearm vasodilatation in patients and 
controls (P<0.0001 for all). Vasodilatation to acetylcholine (P=0.01) but not apelin 
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(P=0.3) or SNP (p=0.9) was attenuated in patients with heart failure. Systemic 
infusions of (Pyr1)apelin-13 increased cardiac index and lowered mean arterial 
pressure and peripheral vascular resistance index in patients and matched controls 
(all P<0.01) but increased heart rate only in controls (P<0.01).  
 
Conclusions   Although having no apparent effect on venous tone, acute apelin 
receptor agonism causes peripheral and coronary vasodilatation and increases cardiac 
contractility and output. Local vascular and systemic haemodynamic responses to 
apelin are preserved in patients with stable symptomatic chronic heart failure. The 
apelin system merits further clinical investigation to determine its role in 
cardiovascular homeostasis and represents a novel potential therapeutic target for 
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1.1 OVERVIEW OF THE APELIN SYSTEM 
 
In 1993 a novel G protein-coupled receptor (GPCR) was identified through 
homology cloning by O’Dowd et al and named ‘APJ’ [O'Dowd et al 1993]. It 
remained an ‘orphan’ receptor until 1998 when its endogenous ligand was identified 
from bovine stomach extracts. The ligand, a 36 amino acid peptide, was named 
‘apelin’ (APJ endogenous ligand) [Tatemoto et al 1998]. Subsequently, in 2008, the 
APJ receptor was renamed the ‘apelin receptor’ by the International Union of 
Pharmacology [Pitkin et al 2010a]. Since its discovery, the apelin system has 
emerged as an important regulator of cardiovascular homeostasis that may play a role 
in the pathophysiology of heart failure and represents an exciting target for the 
development of new therapies [Kleinz and Davenport 2005; Sorli et al 2006; Japp 
and Newby 2008]. 
 
1.2 THE APELIN RECEPTOR 
 
1.2.1   STRUCTURE OF THE APELIN RECEPTOR 
The apelin receptor is highly conserved across a range of species including human, 
rat, mouse, cow and rhesus macaque [Pitkin et al 2010a]. The human apelin receptor 
gene is located on the long arm of chromosome 11 and encodes a 380 amino acid     
GPCR with seven transmembrane-spanning domains [O'Dowd et al 1993]. It most 
closely resembles the angiotensin II type 1 (AT1) receptor, with 54% sequence 
homology in the transmembrane regions, but does not bind angiotensin II. 
Radioligand binding studies in human tissue utilising [125I]-(Pyr1)apelin-13 have 
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suggested a single receptor population with no evidence of distinct receptor subtypes 
[Katugampola et al 2001]. 
 
1.2.2   TRANSCRIPTIONAL REGULATION OF THE APELIN RECEPTOR 
The transcriptional regulation of the apelin receptor gene appears to be complex and, 
at the time of writing, remains poorly understood. Physiological stimuli for apelin 
receptor synthesis include acute and chronic stress [O’Carroll et al 2003], salt 
loading [O’Carroll and Lolait 2003], water deprivation [Azizi et al 2008] and 
hypoxia [Sheikh et al 2008]. At the molecular level, a TATA-less promoter region 
within the gene has been identified [O’Carroll et al 2006]. The transcriptional factor, 
Specificity protein 1 (Sp1), which initiates transcription of several genes whose 
promoters lack a TATA box [Pugh et al 1991], also plays a major role in activation 
of the apelin receptor promoter. Other factors that contribute to promoter activity 
include CCAAT/enhancer binding protein, oestrogen and glucocorticoid protein 
complexes [O’Carroll et al 2006]. 
 
1.2.3   INTRACELLULAR SIGNALLING MECHANISMS 
Apelin inhibits forskolin-stimulated production of cyclic adenosine monophosphate 
(cAMP) in Chinese hamster ovary cells, transfected with the apelin receptor, 
suggesting that the receptor couples to inhibitory G proteins (Gi) [Tatemoto et al 
1998]. Apelin peptides also induce Ras-independent activation of extracellular-
regulated kinases (ERKs) via protein kinase C [Masri et al 2002] as well as 
activation of p70S6 kinase (an important regulator of translation and cell cycle 
progression) through ERK- and Akt-dependent phosphorylation pathways         
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[Masri et al 2004]. These signalling cascades are inhibited by pertussis toxin 
implying that they too are mediated by coupling of the apelin receptor to Gi. On the 
other hand, the inotropic action of apelin is only partially suppressed by pertussis 
toxin and appears to involve activation of phospholipase C and protein kinase C 
[Szokodi et al 2002], a pathway characteristically activated by Gq proteins [Neves et 
al 2002]. This raises the possibility that the receptor may couple to Gq proteins in 
addition to Gi proteins. One well-established effect of phospholipase C activation is 
to increase intracellular production of inositol 1,4,5-trisphosphate (IP3) through 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) [Neves et al 2002]. This 
pathway may account for the observed increase in intracellular calcium (Ca2+) 
concentrations in human NT2-N neurons on exposure to apelin [Choe et al 2000]. 
Activation by apelin peptides causes internalisation of the apelin receptor in a dose-
dependent manner [Zhou et al 2003]. Although the receptor can mediate signal 
transduction from the cell surface, internalisation appears to be critical for activation 
of some downstream signalling pathways including those involved in the depressor 
response to apelin in vivo [El Messari et al 2004]. Receptor internalisation is also 
likely to underpin the desensitisation of several apelin-mediated signalling cascades 
observed following repeated ligand stimulation [Zhou et al 2003; Masri et al 2006]. 
Lee et al have previously demonstrated nuclear localisation of the apelin receptor 
[Lee et al 2004] suggesting the possibility that its effects may extend beyond the 
activation of intracellular cascades to transcriptional regulation, similar to other 
GPCRs such as AT1 [Eggena et al 1993]. Finally, the AT1 and apelin receptors have 
recently been shown to be capable of forming heterodimers [Chun et al 2008] with 
consequences for downstream signalling. The formation of heterodimers is promoted 
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by angiotensin II but unaffected by apelin and is the first apelin-independent action 
of the apelin receptor to be described. Such ligand-independent interactions provide 
one possible mechanism to account for observed phenotypic differences in apelin 
null and apelin receptor null animal models.  
 
1.3 APELIN PEPTIDES 
 
1.3.1   ENDOGENOUS APELIN 
The human apelin gene, located on the long arm of the X chromosome, encodes a 77 
amino acid prepropeptide that undergoes enzymatic cleavage to yield shorter active 
peptides (Figure 1.1) [Tatemoto et al 1998]. To date, the apelin receptor is the only 
receptor with which apelin peptides are known to bind and interact [Pitkin et al 
2010a]. The full-length mature apelin peptide comprises 36 amino acids (apelin-36), 
but shorter fragments of its carboxyl (C)-terminus, consisting of 17 and 13 
amino acids, have also been detected in vivo and exhibit biological activity 
[Tatemoto et al 1998; Habata et al 1999; Hosoya et al 2000]. Apelin-13 undergoes a 
pyroglutamate substitution at its amino (N)-terminus; a common post-translational 
modification that preserves biological activity by rendering the peptide more 
resistant to enzymatic degradation [Van Coillie et al 1998]. (Pyr1)apelin-13 is the 
most abundant isoform in cardiac tissue and plasma [Maguire et al 2009], whilst 
apelin-36 predominates in bovine colostrum [Hosoya et al 2000]. These two peptides 
also display different pharmacodynamic properties: (Pyr1)apelin-13 exhibits greater 
affinity for the apelin receptor but apelin-36 is less readily displaced [Hosoya et al 
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Figure 1.1  Apelin synthesis, post-translational processing and metabolism. 









(Pyr1)apelin-13 are rapidly recycled to the cell surface whereas those bound by 
apelin-36 remain within the cell cytoplasm for at least 2 hours [Zhou et al 2003]. In 
keeping with these findings, (Pyr1)apelin-13 is the more potent isoform in 
competitive inhibition assays, but the biological effects of apelin-36 are more 
sustained [Hosoya et al 2000, Masri et al 2006]. The distinct physiological roles of 
the different apelin peptides remain uncertain.  
 
Expression of the apelin gene in several tissues is increased in response to hypoxia 
under the regulation of hypoxia-inducible factor-1 [Ronkainen et al 2007; Sheikh et 
al 2008]. In breast tissue, there is up regulation of apelin synthesis during lactation 
that is mediated by upstream stimulatory factor-1 [Wang et al 2006], a fairly 
ubiquitous transcription factor involved primarily in energy metabolism and cellular 
proliferation [Corre and Galibert 2006]. In adipocytes, apelin gene expression is 
inhibited in the fasting state and stimulated by refeeding possibly through changes in 
the plasma concentrations of insulin and counter-regulatory hormones [Boucher et al 
2005; Wei et al 2005]. Finally, in magnocellular neurons of the hypothalamus, apelin 
is up regulated by dehydration, through a mechanism that may involve arginine 
vasopressin (AVP) [Reaux-Le Goazigo et al 2004].  
 
Less is known about the mechanisms regulating the post-translational processing of 
apelin including the proteolytic cleavage of the longer apelin isoforms to shorter C-
terminal fragments and the pyroglutamine modification of apelin-13. One enzyme 
implicated in the processing of apelin peptides is angiotensin-converting 
enzyme (ACE) type 2, a carboxypeptidase that negatively regulates the              
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renin-angiotensin-aldosterone system (RAAS) by cleaving angiotensin II to the 
biologically inactive peptide angiotensin 1-9 or angiotensin 1-7 [Hamming et al 
2007]. ACE type 2 has been reported to hydrolyse both apelin-13 and apelin-36 with 
high catalytic efficiency [Vickers et al 2002]. However, the physiological 
significance of this step remains unclear and recent in vitro data suggest it may not 
lead to inactivation of the peptide [Pitkin et al 2010a].  
 
1.3.2   SYNTHETIC APELIN RECEPTOR AGONISTS 
Several other fragments of the apelin peptide activate the apelin receptor and produce 
biological effects although their presence in vivo has yet to be established. The C-
terminal portion of the apelin peptide is highly conserved across species and appears 
to be critical to biological activity: synthetic peptide fragments containing the final 
12 residues of the C-terminus, including apelin-19, apelin-16 and apelin-12, display 
agonist activity whilst those shorter than 12 amino acids are biologically inert        
[El Messari et al 2004]. Recently, Iturrioz et al have developed the first non-peptidic 
apelin agonist, E339-3D6, an important step toward exploring the therapeutic 
potential of apelin analogues [Iturrioz et al 2010]. 
 
1.3.3  APELIN RECEPTOR ANTAGONISTS 
Apelin-13(F13A), a synthetic analogue of apelin-13 with an alanine substitution at 
the C-terminus, was initially reported to antagonise the depressor effect of apelin-13 
in rats in vivo, without affecting basal blood pressure [Lee et al 2005]. However 
other investigators have been unable to demonstrate its antagonistic activity in vitro 
[Fan et al 2003; Medhurst et al 2003]. In recent months, and subsequent to the 
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undertaking of this thesis, Macaluso et al have developed the first small-molecule 
apelin antagonist, cyclo(1-6)CRPRLC-KH-cyclo(9-14)CRPRLC that competitively 
inhibits apelin-induced receptor internalisation and inhibition of cAMP production in 
cell lines transfected with the human apelin receptor [Macaluso et al 2011].  
 
1.4 LOCALISATION OF THE APELIN SYSTEM 
 
1.4.1   APELIN RECEPTOR LOCALISATION 
In both rat and human, the apelin receptor is widely represented in the central 
nervous system (CNS) and a variety of peripheral tissues [Pitkin et al 2010a]. Within 
the rat brain, expression is particularly high in magnocellular neurons of the 
supraoptic and paraventricular hyopthalamic nuclei, where it colocalises with AVP 
[De Mota et al 2004; Reaux-Le Goazigo et al 2004]. Within some peripheral tissues, 
such as lung, kidney and adrenal gland, expression appears to be restricted to the 
vasculature [Kleinz et al 2005], though apelin receptors have also been detected in 
enterochromaffin-like gastric cells [Lambrecht et al 2006], pancreatic islet cells 
[Sörhede Winzell et al 2005], hepatic stellate cells [Melgar-Lesmes et al 2011], 
adipocytes [Wei et al 2005], osteoblasts [Xie et al 2006] and T-lymphocytes [Choe 
et al 1998]. Within the human vasculature, apelin receptor protein is detectable in 
large conduit arteries (radial, mammary, coronary) and veins (saphenous), and in 
small vessels from a variety of vascular beds [Kleinz et al 2005]. Receptors are 
located predominantly within the endothelium but are also present, at lower levels, in 
vascular smooth muscle cells. Within the human heart, apelin receptors are present in 
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endocardial endothelial cells and, at lower levels, in cardiomyocytes [Kleinz et al 
2005]. 
 
1.4.2   APELIN PEPTIDE LOCALISATION 
The expression pattern of apelin is closely related to that of the apelin receptor. 
Within the human vasculature, apelin is detectable in large conduit vessels including 
radial artery, left internal mammary artery, coronary artery and saphenous vein, as 
well as renal, adrenal and pulmonary vessels [Kleinz and Davenport 2004]. 
However, unlike the receptor, its expression appears to be restricted to the 
endothelium [Kleinz and Davenport 2004; Sheikh et al 2008]. Recently, apelin 
protein has been detected within atherosclerotic plaque of human coronary artery 
where it colocalises with both the apelin receptor and with markers of smooth muscle 
cells and macrophages [Pitkin et al 2010b]. Within the human heart, expression 
appears to be restricted to endocardial endothelial cells [Kleinz and Davenport 2004]. 
 
1.4.3   AUTOCRINE, PARACRINE OR ENDOCRINE SYSTEM? 
The colocalisation of apelin and the apelin receptor in many tissues suggests a 
possible autocrine or paracrine signalling pathway. In keeping with this, the receptor 
and ligand exhibit co-ordinated tissue-specific changes in expression under different 
physiological conditions such as hypoxia [Sheikh et al 2008] and obesity [Dray et al 
2010]. Accurate quantification of apelin concentration in plasma has been 
confounded by limitations in the sensitivity and use of commercially available assays 
[Japp and Newby 2008]. This has led to marked discrepancies in measured 
concentrations with around 40-fold variation (90-3,580 pg/mL) being reported 
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among healthy control populations [Földes et al 2003; Chong et al 2006]. However 
this is likely to reflect insufficient extraction of plasma proteins in some studies, 
resulting in non-specific binding and reporting of falsely elevated plasma apelin 
concentrations [Barnes et al 2010]. Recent studies combining improved assay 
technology with more exact methodology suggest concentrations in the subpicomolar 
range, lower than would be expected for a circulating peptide [Pitkin et al 2010b]. 
The main source of plasma apelin is currently unclear although adipose tissue and 
the vascular endothelium are likely to contribute.  
 
1.5 PHYSIOLOGICAL ROLES OF THE APELIN SYSTEM 
 
1.5.1   OVERVIEW OF PHYSIOLOGICAL FUNCTIONS 
In keeping with its widespread pattern of expression, the apelin system has been 
implicated in a variety of physiological functions. Whilst the clearest evidence to 
date for a physiological role is in the regulation of cardiovascular homeostasis, apelin 
signalling appears to influence a number of other physiological processes [Sorli et al 
2006; Barnes et al 2010; Pitkin et al 2010a]. In addition to the specific areas 
discussed below, emerging evidence suggests a role for the apelin pathway in 
thermoregulation [Jászberényi et al 2004], immune function [Cayabyab et al 2000], 
bone metabolism [Xie et al 2007], gut hormone secretion [Lambrecht et al 2006] and 





1.5.2   FLUID HOMEOSTASIS 
In rats, the apelin system is highly expressed in regions of the CNS critical to 
osmotic regulation, including magnocellular neurons of the hypothalamic supraoptic 
and paraventricular nuclei (PVN) [O’Carroll and Lolait 2003; De Mota et al 2004]. 
Here, both apelin and its receptor colocalise with AVP, a key modulator of water 
homeostasis released during increased plasma osmolality or reduced plasma volume 
to promote water retention by renal collecting duct cells. Apelin synthesis is 
increased in response to water deprivation under the actions of AVP [O’Carroll et al 
2003; Reaux-Le Goazigo et al 2004]. In turn, intracerebral injection of apelin 
directly inhibits AVP neuron activity and induces a diuresis with little or no apparent 
increase in sodium excretion [De Mota et al 2004]. In addition to its central 
interactions with AVP, apelin also exerts vasoactive effects on the renal 
microvasculature and may modulate fluid balance through direct effects on 
glomerular haemodynamics [Hus-Citharel et al 2008]. Recent studies in apelin 
receptor knockout mice appear to confirm an important physiological role for 
endogenous apelin signalling in fluid homeostasis: mice lacking the apelin receptor 
gene exhibit reduced drinking behaviour under basal conditions and an inability to 
concentrate urine in response to osmotic challenge [Roberts et al 2009]. To date, 
clinical data are limited but, in healthy volunteers, water loading results in elevated 
plasma apelin concentrations, whilst increased plasma osmolality causes plasma 
apelin concentrations to fall; in each case there is a reciprocal change in AVP 
concentration [Azizi et al 2008]. Taken together, these data suggest that apelin may 
play an important counter-regulatory role to AVP in fluid homeostasis. 
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1.5.3  ENERGY METABOLISM 
Apelin is produced by adipose tissue and influences glucose metabolism [Boucher et 
al 2005]. In preclinical models, apelin inhibits insulin secretion by pancreatic islet 
cells [Sörhede Winzell et al 2005] and increases peripheral glucose uptake through a 
direct action on skeletal muscle [Yue et al 2010]. Accordingly, exogenous apelin in 
rodents reduces peak plasma glucose concentrations following a glucose load in both 
healthy and insulin-resistant animals [Dray et al 2008]. Furthermore, mice with 
deletion of the apelin gene exhibit impaired insulin sensitivity that is reversed by 
exogenous apelin supplementation [Yue et al 2010]. The effect of exogenous apelin 
on glucose handling in man is currently unknown. However, increases in plasma 
apelin concentrations are seen during oral glucose tolerance tests in healthy 
individuals, and those with insulin resistance or type 2 diabetes mellitus [Li et al 
2006]. Apelin signalling also appears to regulate lipid metabolism. Apelin inhibits 
lipolysis in cultured adipocytes [Yue et al 2011] whilst mice with deletion of the 
apelin gene display increased plasma levels of free fatty acids and glycerol, an effect 
reversed by exogenous apelin replacement [Yue et al 2010]. Finally, in murine 
models, both endogenous and exogenous apelin appears to decrease adiposity 
without affecting food intake [Higuchi et al 2007; Yue et al 2010].   
 
1.5.4   CARDIOVASCULAR DEVELOPMENT AND ANGIOGENESIS 
In a variety of in vitro and preclinical in vivo models apelin exerts potent angiogenic 
and mitogenic effects [Kasai et al 2004; Cox et al 2006; Sorli et al 2007]. In several 
species, during embryonic development, apelin receptors are expressed in endothelial 
progenitor cells and rudimentary cardiovascular structures [Cox et al 2006; Zeng et 
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al 2007; Kidoya et al 2008] and endogenous apelin signalling appears to be essential 
for normal cardiovascular development. In the developing zebrafish [Scott et al 
2007; Zeng et al 2007] and frog [Cox et al 2006], altered expression of either the 
ligand or receptor gene disrupts vascular development and produces morphological 
cardiac abnormalities. In mice deletion of the apelin gene during embryogenesis 
retards retinal vascular development [Kasai et al 2008], whilst knockout of the apelin 
receptor gene results in developmental cardiac defects [Charo et al 2009]. 
 
The angiogenic effects of apelin signalling appear to extend beyond foetal life. Both 
apelin and the apelin receptor are up regulated by hypoxia in a range of tissues 
[Ronkainen et al 2007; Sheikh et al 2008; Geiger et al 2011; Melgar-Lesmes et al 
2011] and apelin signalling promotes neovascularisation of adipose tissue 
[Kunduzova et al 2008] and solid tumours [Sorli et al 2007]. Apelin deficiency has 
been shown to decrease the hypoxia-induced regeneration of vessels in zebrafish, 
[Eyries et al 2008] and to worsen necrosis in a model of hind limb ischaemia in mice 
[Kidoya et al 2010]. Furthermore, in the latter model, exogenous apelin 









1.6 VASCULAR EFFECTS OF APELIN 
 
1.6.1   VASCULAR EFFECTS IN VITRO 
Apelin activates endothelial nitric oxide synthase (eNOS) in cultured human 
umbilical vein endothelial cells [Ishida et al 2004] possibly via Akt phosphorylation, 
and stimulates nitric oxide production in rat aorta [Jia et al 2007]. In keeping with 
this, apelin causes vasorelaxation in ex vivo human mesenteric arteries that is 
attenuated by nitric oxide synthase but not cyclooxygenase inhibition [Salcedo et al 
2007]. However, it also stimulates myosin-light chain phosphorylation in rat and 
mouse vascular smooth muscle [Hashimoto et al 2006], a key step in contraction and 
causes constriction ex vivo in human saphenous vein and internal mammary artery 
denuded of endothelium [Katugampola et al 2001]. Collectively these data suggest 
that apelin can act directly on receptors within vascular smooth muscle to induce 
contraction but that in the presence of functioning endothelium, this effect is 
outweighed by stimulation of local nitric oxide production via endothelial apelin 
receptors (Figure 1.2).  
 
1.6.2   VASCULAR EFFECTS IN VIVO IN ANIMAL MODELS 
Apelin was originally shown to cause a rapid and transient fall in mean arterial 
pressure following bolus injection in rats [Lee et al 2000]. This finding in rodents 
has been widely replicated [Reaux et al 2001; Tatemoto et al 2001; El Messari et al 
2004; Ishida et al 2004; Lee et al 2005; Jia et al 2006] but is absent in mice with 
targeted knockout of the apelin receptor gene, confirming that it is mediated via 
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the apelin receptor [Ishida et al 2004]. In keeping with in vitro data, the depressor 
response is also abolished by co-administration of Nω-nitro-L-arginine-methyl ester 
(L-NAME), a nitric oxide synthase inhibitor, suggesting it occurs through nitric 
oxide-mediated arterial vasodilatation [Tatemoto et al 2001].  
 
Bolus intravenous apelin injection reduces mean circulatory filling pressure [Cheng 
et al 2003], an accurate reflection of systemic venous tone [Pang 2000] implying that 
apelin can function as both an arterial and venous dilator. Indeed, by this measure, 
apelin is a more efficacious venodilator than either nitrates or hydralazine. These 
changes in vascular tone are matched by corresponding alterations in ventricular 
loading conditions: acute apelin administration reduces left ventricular end-diastolic 
area and left ventricular end-systolic pressure [Ashley et al 2005] To date there have 
been no reports of apelin-mediated vasoconstriction in vivo. 
 
Currently there are no reports of the in vivo effects of apelin in man. However the 
only in vivo study in large mammals to date has raised the possibility that 
cardiovascular responses to apelin may exhibit interspecies differences. Acute bolus 
administration of apelin in an ovine model at equivalent doses to rodent studies 
elicited a biphasic haemodynamic response with an initial transient reduction in 
arterial pressure and rise in heart rate followed rapidly by an increase in blood 
pressure and concomitant fall in heart rate [Charles et al 2006]. Cardiac output was 
not measured early in this study but fell during the hypertensive phase, paralleling 
the reduction in heart rate and coinciding with rises in peripheral vascular resistance 
and right atrial pressure.  
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1.6.3   VASCULAR EFFECTS OF ENDOGENOUS APELIN 
The lack of a suitable apelin receptor antagonist has prevented detailed 
characterisation of the role of endogenous apelin in the regulation of vascular tone. 
Murine models with targeted deletion of either the apelin [Kuba et al 2007] or apelin 
receptor [Ishida et al 2004] gene have normal basal blood pressure. However mice 
with apelin receptor deletion exhibit an exaggerated pressor response to 
angiotensin II [Ishida et al 2004]. Furthermore additional deletion of the apelin 
receptor in mice already lacking the AT1 receptor causes an increase in basal blood 
pressure. Together, these effects suggest a possible contribution from endogenous 
apelin signalling to basal vascular dilator tone.  
 
1.7 CARDIAC EFFECTS OF APELIN 
 
1.7.1   CARDIAC EFFECTS OF APELIN IN VITRO 
In keeping with the localisation of apelin receptors within the heart, apelin exhibits 
direct myocardial effects. In isolated rat hearts, apelin increases contractility at 
subnanomolar concentrations and augments the preload-induced increase in the 
maximum rate of rise in pressure (dP/dtmax) within the left ventricle [Szokodi et al 
2002]. Apelin also induces sacromere shortening in individual cardiomyocytes 
obtained from both normal and failing myocardium [Farkasfalvi et al 2007] and 
increases contractility in isolated right ventricular trabeculae from failing rat hearts 
[Dai et al 2006]. Although these studies all support a positive inotropic role for 
apelin, there are discrepancies in the reported findings. Whilst the reported EC50 
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value for apelin in normal intact rat hearts was 33 pM, making apelin the most potent 
inotrope yet studied, concentrations more than 1000-fold higher failed to elicit an 
increase in contractility in normal rat trabeculae, and produced only a very modest 
response in failing trabeculae. In addition the slow-onset sustained increase in 
contractility over a period of 30 minutes observed in the intact rat heart model, 
contrasts sharply with the transient response of only 1-2 minutes seen in single 
cardiomyocytes. Such discrepancies may be attributable to the different 
methodologies employed or regional variation in the density of apelin receptors 
within the heart. In isolated cardiomyocytes, the absence of mechanical load may 
have contributed to a more limited response, especially as apelin only increased 
preload-induced dP/dtmax in intact hearts, at higher loading conditions. Given the 
preferential localisation of both receptor and ligand in endocardial cells over 
cardiomyocytes, it is also tempting to speculate that signal transduction from 
activated endocardial apelin receptors might play a predominant role in mediating 
the inotropic effects of apelin. If so, preservation of this signalling pathway in intact 
hearts might account for the greater responses to apelin seen in this model. At the 
time this thesis was undertaken, there were no reports of the direct effects of apelin 
on human cardiac tissue. However Maguire et al [Maguire et al 2009] have recently 
confirmed potent inotropic activity ex vivo in human paced atrial strips. 
 
1.7.2   CARDIAC EFFECTS OF APELIN IN VIVO IN ANIMAL MODELS 
The inotropic effects of the apelin system in rodents extend to the in vivo setting 
where acute apelin infusion increases left ventricular dP/dtmax and cardiac output 
[Berry et al 2004; Jia et al 2006; Atluri et al 2007] as well as load-independent 
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measures of myocardial contractility such as ventricular elastance and preload 
recruitable stroke work [Ashley et al 2005]. Importantly, chronic administration also 
leads to an increase in cardiac output without inducing left ventricular hypertrophy 
[Ashley et al 2005].  
 
1.7.3   THE ROLE OF ENDOGENOUS APELIN SIGNALLING IN CARDIAC REGULATION 
Mice with targeted knockout of either the apelin or apelin receptor gene exhibit 
normal cardiac development and baseline haemodynamic parameters but have 
striking impairment of sarcomeric function accompanied by reduced cardiac 
contractility and diminished exercise capacity [Charo et al 2009]. Apelin null mice 
subjected to chronic pressure overload with aortic banding develop severe heart 
failure compared with wild-type mice and, even in the absence of aortic banding, 
develop progressive left ventricular dysfunction and dilatation from around 6 months 
of age [Kuba et al 2007]. Exogenous replacement of apelin in adult life prevents this 
age-related decline in cardiac performance, suggesting it is attributable to 
contemporary loss of apelin activity and not the manifestation of a latent 
developmental defect. In comparison to mice with deletion of the apelin gene, those 
with deletion of the apelin receptor exhibit poorer effort tolerance, earlier 
echocardiographic evidence of left ventricular dysfunction [Charo et al 2009] and 
reduced survival during embryogenesis [Charo et al 2009]. Such phenotypic 
differences suggest either ligand-independent effects of the apelin receptor or an 
undiscovered ligand. Taken together the above genetic data imply an important role 
for endogenous apelin signalling in maintaining cardiac performance both under 
basal conditions and particularly during conditions of cardiovascular stress.  
 33 
 
1.7.4   MECHANISMS OF APELIN-MEDIATED INOTROPY 
The mechanisms by which apelin exerts its inotropic effects have been only partially 
elucidated and remain the subject of debate. The effects are independent of 
angiotensin II, endothelin-1, catecholamines and nitric oxide release [Szokodi et al 
2002] but appear to involve activation of the sacrolemmal Na+/H+ exchanger (NHE), 
probably through phospholipase C and protein kinase C-dependent pathways 
(Figure 1.3) [Szokodi et al 2002; Farkasfalvi et al 2007]. In single cardiomyocytes, 
NHE activity increases following exposure to apelin while, in intact rat hearts, the 
inotropic response to apelin is markedly attenuated by a specific inhibitor of NHE. 
Stimulation of NHE can lead to intracellular alkalinisation and sensitisation of 
cardiac myofilaments to intracellular Ca2+ [Karmazyn et al 1999]. In keeping with 
this, activation of NHE by apelin is accompanied by an increase in intracellular pH 
[Farkasfalvi et al 2007], whilst cytoplasmic Ca2+ transients are unchanged and 
perforated patch clamp recordings show that apelin does not alter voltage-gated Ca2+ 
channels in cardiomyocytes. Furthermore, in cardiomyocytes isolated from mice 
lacking either the apelin or apelin receptor gene, sarcomeric function is impaired 
without any corresponding alterations in intracellular calcium transients [Charo et al 
2009]. These data suggest that apelin increases myocardial contractility by enhancing 
the sensitivity of myofilaments to activator Ca2+ rather than increasing intracellular 
Ca2+ concentrations. However, activation of NHE can also indirectly increase 
intracellular Ca2+ as the resulting accumulation of Na+ within cells stimulates the 
reverse mode Na+/Ca2+ exchanger (NCX) [Kentish 1999]. In intact rat hearts, 






























Figure 1.3  Possible intracellular mechanisms of apelin-mediated positive inotropic effects. Ap - 
apelin; ApR - apelin receptor; Gq - Gq protein; PLC - Phospholipase C; SR - sacroplasmic reticulum; 
Ca++ - calcium; NHE - Na+/H+ exchanger; NCX - reverse Na+/Ca2+ exchanger; PIP2 - 
phosphatidylinositol 4,5-bisphosphate; IP3 - inositol 3,4,5 trisphosphate; DAG - diacylglycerol. 
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that this mechanism may contribute to apelin-mediated inotropic activity. 
Furthermore, in failing rat trabeculae, apelin failed to alter steady-state force-[Ca2+]i 
relations but increased the amplitude of the intracellular Ca2+ transient [Dai et al 
2006]. Thus the inotropic effects of apelin may involve increased intracellular Ca2+ 
availability in addition to enhanced myofilament responsiveness to Ca2+.  
 
1.8 THE APELIN SYSTEM IN HEART FAILURE 
 
1.8.1   ALTERED EXPRESSION OF THE APELIN SYSTEM IN PRECLINICAL MODELS OF 
HEART FAILURE 
Expression of apelin and its receptor is increased or maintained in animals with left 
ventricular hypertrophy and compensated heart failure but down regulated in those 
with severe, decompensated heart failure [Iwanaga et al 2006; Jia et al 2006]. This 
down regulation may be related to increased activity of the RAAS. In one heart 
failure model, several pharmacological treatments retarded the progression to chronic 
heart failure, but only AT1 receptor antagonism prevented the down regulation of 
apelin receptor and ligand expression [Iwanaga et al 2006]. Furthermore, infusion of 
angiotensin II over 24 hours, even at subpressor doses, reduced both apelin and 
apelin receptor expression, and this effect was also abolished by concurrent AT1 
receptor blockade. Cardiac dilatation in advanced heart failure may also contribute to 
down regulation of the apelin system since cardiomyocytes subjected to mechanical 
stretch in vitro exhibit markedly reduced expression of both the apelin receptor and 
ligand [Szokodi et al 2002]. 
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Regulation of the apelin pathway is altered by acute ischaemic injury. Apelin gene 
expression and secretion in isolated cardiomyocytes is increased by acute hypoxia 
through the hypoxia inducible factor pathway [Ronkainen et al 2007]. Accordingly, 
apelin expression is up regulated in vivo within 24 hours of myocardial infarction 
[Ronkainen et al 2007]. Endogenous cardiac apelin and the apelin receptor are 
increased in rats with ischaemic heart failure 6 weeks post myocardial infarction 
[Atluri et al 2007]. It is not clear whether the stimulus for this up regulation is 
ischaemia or the early onset of heart failure. In contrast, both receptor and ligand 
expression fall in a further rodent model of ischaemic myocardial injury caused by 
repeated isoprotenerol administration [Jia et al 2006]. This model produced 
extensive myocardial injury and very severe heart failure associated with 
hypotension and grossly elevated left ventricular end-diastolic pressure (LVEDP). 
Interestingly, while cardiac apelin receptor messenger ribonucleic acid (mRNA) 
levels were markedly down regulated in these rats, both tissue levels and overall 
apelin-binding capacity of the receptor within the heart were increased. This might 
reflect more efficient post-transcriptional processing of apelin receptor and / or 
diminished breakdown of existing receptors. 
 
1.8.2   ALTERED EXPRESSION OF THE APELIN SYSTEM IN PATIENTS WITH HEART 
FAILURE 
In keeping with the findings from preclinical models, expression of the apelin 
pathway is altered in patients with chronic heart failure. Initial reports suggested that 
plasma apelin concentrations were mildly elevated in the early stages of heart failure 
but fell with more advanced disease [Chen et al 2003; Földes et al 2003]. In support 
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of this, there are now several further reports of depressed plasma apelin 
concentrations in patients with advanced chronic heart failure [Chong et al 2006; 
Goetze et al 2006; Francia et al 2007]. Furthermore, in patients with severe chronic 
heart failure, the improvement in New York Heart Association (NYHA) symptom 
class  and left ventricular ejection fraction seen following cardiac resynchronisation 
therapy is paralleled by restoration of normal plasma apelin concentration [Francia et 
al 2007]. Some subsequent studies have produced conflicting findings and, as 
described above, this may in part reflect significant limitations in currently available 
commercial assays for apelin. However careful scrutiny suggests that apparent 
inconsistencies may also be attributable to differences in study populations       
(Table 1.1). For example, Chong and co-workers reported that plasma apelin 
concentrations were lower in patients with chronic heart failure than in normal 
controls irrespective of NYHA symptom class or left ventricular ejection fraction 
[Chong et al 2006]. However these investigators studied a cohort of patients with 
disproportionately severe heart failure: 73% of patients were NYHA class III or IV 
and only 3% were NYHA class I. Moreover mean ejection fraction was 15% and, 
even in NYHA class II patients, it was a mere 18%. In contrast two subsequent 
studies have since claimed that plasma apelin concentrations are unaltered in patients 
with chronic heart failure compared with age-matched controls [Codognotto et al 
2007; Miettinen et al 2007]. However in both of these studies, more than 95% of 
patients were in NYHA functional class I or II, and the average left ventricular 
ejection fraction was 40% and 42% respectively. Therefore, taken together, current 
data suggest that apelin expression is at least maintained and possibly augmented in 













































































































































































































































































































































































































































Apelin receptor mRNA levels within the left ventricle are reduced in patients with 
advanced heart failure due to idiopathic dilated cardiomyopathy but unaltered in 
patients with ischaemic cardiomyopathy [Földes et al 2003], perhaps reflecting the 
stimulatory effect of local hypoxia on receptor expression. On the other hand, apelin 
receptor density within the left ventricle is reduced in both ischaemic and non-
ischaemic cardiomyopathy [Pitkin et al 2010b]. The reduction in receptor density in 
the absence of changes in expression in ischaemic heart failure may reflect 
alterations in post-transcriptional processing or, alternatively, greater internalisation 
of the receptor due to increased ligand activation. Apelin expression is increased in 
failing human left ventricle irrespective of aetiology whilst protein levels are 
unchanged [Földes et al 2003]. Interestingly, myocardial expression of the apelin 
receptor gene and cardiac apelin tissue concentrations were markedly increased 
following offloading of the ventricle by implantation of a left ventricular assist 
device [Chen et al 2003]. 
 
1.8.3   EFFECTS OF EXOGENOUS APELIN ADMINISTRATION IN PRECLINICAL MODELS 
OF HEART FAILURE  
The ability of apelin peptides to enhance contractility in healthy myocardium whilst 
simultaneously reducing loading conditions suggests potential therapeutic 
application in heart failure. Crucially, these effects are maintained and possibly 
amplified in the failing heart. Apelin increases contractility in vitro to the same or 
even greater extent in failing myocardium as it does in normal myocardium [Dai et al 
2006; Farkasfalvi et al 2007]. In vivo, in rats with established heart failure 
post myocardial infarction, apelin infusion restores ejection fraction, increases 
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cardiac output and reduces LVEDP [Berry et al 2004; Atluri et al 2007]. 
Furthermore, in a rat model of severe heart failure that exhibits features of 
cardiogenic shock, apelin improved cardiac contractility, loading conditions and 
blood pressure despite a reduction in myocardial apelin receptor expression of over 
50% [Jia et al 2006]. These findings suggest that the signalling capacity of cardiac 
apelin receptors is not exhausted even when endogenous apelin receptor expression 
is diminished.  
 
The beneficial effects of exogenous apelin administration may extend beyond 
improving cardiac performance in established heart failure to affording 
cardioprotection during myocardial injury. In the isoprotenerol heart failure model 
outlined above, concurrent administration of apelin preserved cardiac function and 
reduced indices of myocardial injury, preventing the development of heart failure 
[Jia et al 2006]. Moreover, in rat models of myocardial infarction, bolus infusion of 
apelin at the time of reperfusion, reduced infarct size in vitro and in vivo by 39% and 
43% respectively [Simpkin et al 2007]. The reduction in infarct size was associated 
with activation of components of the reperfusion injury salvage kinase pathway, a 
key cell-signalling system that protects against ischaemia-reperfusion injury 
[Hausenloy et al 2004]. In light of this, the aforementioned up regulation of apelin 
expression in response to ischaemia may serve as an endogenous cardioprotective 




1.8.4   POTENTIAL THERAPEUTIC ROLE OF APELIN RECEPTOR AGONISM IN 
PATIENTS WITH HEART FAILURE 
In preclinical models, exogenous apelin reduces ventricular preload and afterload 
and increases myocardial contractility whilst endogenous apelin maintains cardiac 
performance during ageing and pressure overload. Rodents with heart failure exhibit 
down regulation of the apelin pathway that parallels the decline in cardiac function, 
yet the favourable haemodynamic effects of exogenous apelin are maintained. 
Together, these data suggest that augmentation of apelin signalling holds major 
promise for the treatment of heart failure, particularly as the apelin system undergoes 
a similar down regulation in patients with advanced chronic heart failure.  
 
The first tentative evidence that disturbed endogenous apelin signalling may have 
functional relevance in human heart failure was recently provided in a cohort of 
patients with dilated cardiomyopathy [Sarzani et al 2007]. In these patients, 
possession of a polymorphism of the apelin receptor, 212A (the biological 
significance of which is unknown) was associated with slower progression of heart 
failure. Notably, no difference in the frequency of this polymorphism was noted 
between dilated cardiomyopathy patients and controls, suggesting that the 
pathophysiological significance of apelin signalling in heart failure may not relate to 
causation of heart failure per se, but rather in modulating the progression of 
myocardial dysfunction.  
 
However, to date, there are no data on the cardiovascular effects of apelin in vivo in 
man. Detailed clinical investigation is therefore required to establish the role of 
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apelin in human cardiovascular physiology and pathophysiology, and to determine 




In a series of in vivo clinical studies, I will address the following hypotheses: 
In healthy volunteers: 
1. Apelin receptor agonism causes vasodilatation in dorsal hand veins and 
forearm resistance vessels via the endothelial release of nitric oxide and 
prostacyclin.  
2. Systemic apelin receptor agonism increases cardiac output whilst reducing 
peripheral vascular resistance and blood pressure. 
3. Apelin-36 elicits more sustained cardiovascular effects than (Pyr1)apelin-13. 
 
In patients attending for diagnostic coronary angiography without obstructive 
coronary artery disease: 
1. Intracoronary apelin administration increases coronary blood flow and left 
ventricular contractility. 
 
In patients with chronic heart failure: 
1. Direct vascular and systemic haemodynamic responses to apelin are 






The aims of this thesis were: 
In healthy volunteers (Chapter 3): 
• To establish the safety and tolerability of local intra-arterial and intravenous 
infusion of apelin peptides. 
• To determine the direct in vivo actions of acute apelin receptor agonism on 
peripheral venous and resistance vessel tone. 
• To compare the direct vascular actions of apelin-36 and (Pyr1)apelin-13. 
 
In patients attending for diagnostic coronary angiography (Chapters 3 and 5): 
• To establish the direct actions of apelin receptor agonism on coronary blood 
flow and left ventricular contractility. 
 
In healthy volunteers (Chapter 4): 
• To characterise the onset, offset, reproducibility and sustainability of 
vasomotor responses to apelin-36 and (Pyr1)apelin-13. 
• To determine the contribution of the endothelium-derived vasodilators, nitric 
oxide and prostacyclin, to apelin-mediated vasodilatation. 
 
In healthy volunteers (Chapter 5): 
• To establish the effects of systemic apelin receptor agonism on cardiac 
output, peripheral vascular resistance blood pressure and heart rate. 
 44 
• To compare the systemic haemodynamic effects of apelin-36 and 
(Pyr1)apelin-13. 
 
In patients with stable chronic heart failure (Chapter 6): 
• To compare the direct vascular, systemic haemodynamic and neurohormonal 
responses to acute apelin receptor agonism with age- and sex-matched 



















Previous studies of apelin peptides have been carried out in vitro and in animal 
models but their effects have not been previously studied in vivo in man. Combined 
with local drug infusions, the Aellig hand vein technique and bilateral forearm 
venous occlusion plethysmography are ideal methods for assessing the direct 
vascular effects of novel agents in vivo as the use of subsystemic doses minimises the 
risk of harmful effects and avoids potentially confounding effects on other organs 
such as the heart and kidney. Similarly, intracoronary drug administration permits 
assessment of the direct actions of novel agents on the heart and coronary circulation. 
Regional infusion studies can then be followed by systemic administration to allow 
assessment of the net effects on systemic haemodynamics. An overview of the 
techniques employed in this thesis is presented below. Details specific to each study 
can be found in the methods section of subsequent chapters. 
 
2.1.1   AELLIG HAND VEIN TECHNIQUE 
The Aellig hand vein technique is a safe and reproducible method for assessing 
direct pharmacological effects on venous tone in vivo [Aellig 1981; Aellig 1994a; 
Aellig 1994b]. A linear variable differential transformer (LVDT) is used to measure 
changes in the diameter of a single dorsal hand vein at a standardised congestion 
pressure during local drug infusion. When the venous pressure remains constant, 
changes in venous diameter are proportional to changes in venous tone. Thus in vivo 
venomotor responses to infused drugs can be studied in a single vein at locally active 
doses without confounding systemic influences.  
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2.1.2   FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY 
Bilateral forearm venous occlusion plethysmography, combined with unilateral 
intrabrachial drug infusion is an extensively validated, accurate and reproducible 
method of directly assessing the local effects of vasoactive agents in vivo [Walker et 
al 2001; Wilkinson and Webb 2001]. When examining in vivo vascular responses in 
man, systemic drug administration causes concomitant effects on organs, such as the 
brain, kidney and heart, and influences neurohumoral reflexes through changes in 
systemic haemodynamics. Because of these confounding influences, vascular 
responses cannot be wholly attributed to a direct effect of the drug. However, 
forearm vascular responses to intrabrachial drug infusion can be studied at doses    
10-1000-fold lower than those required to elicit a systemic effect. This reduction in 
dose not only avoids confounding systemic effects but minimises the potential for 
side effects and toxicity.  
 
Cuffs secured around the upper arms are intermittently inflated to above venous 
pressure but below diastolic pressure. During cuff inflation, venous drainage from 
the forearm is prevented whilst arterial inflow is unaltered. This results in a linear 
increase in forearm volume over time, proportional to arterial blood flow, that is 
detected by mercury-in-silastic strain gauges placed around the forearm. Under 
resting conditions, approximately 70% of total forearm blood flow (FBF) is through 
skeletal muscle and alterations in blood flow (assuming no change in cardiac output) 
predominantly reflect changes in peripheral resistance vessel tone. As the hand 
contains a high proportion of arteriovenous shunts and because skin blood flow is 
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highly dependent on temperature, the hands are excluded from the circulation during 
measurements by inflation of cuffs, placed around the wrists, to suprasystolic 
pressure. The non-infused arm serves as a contemporaneous control during studies, 
allowing changes in infused arm blood flow to be attributed to local vascular effects 
rather than changes in systemic haemodynamics. 
 
2.1.3   CORONARY BLOOD FLOW AND LEFT VENTRICULAR PRESSURES 
Although concordance between vasomotor responses in the forearm and other 
vascular beds is generally good, differences do exist [Hirooka et al 1994; Wilkinson 
and Webb 2001] and findings cannot be extrapolated to the coronary arterial 
circulation. Intracoronary drug administration with simultaneous measurement of 
coronary blood flow allows assessment of the direct vascular effects on the coronary 
circulation [Newby 2000]. Similar to the Aellig technique and forearm venous 
occlusion plethysmography, local intracoronary injection has the advantage of 
assessing the heart and coronary circulation in relative isolation without inducing 
systemic effects. In addition, relatively high doses can be administered locally which 
may be necessary to achieve the desired physiological or therapeutic effect. 
Measurement of coronary blood flow velocity can be achieved with a Doppler flow 
wire, a miniature Doppler ultrasound crystal mounted on the tip of a 0.014-inch 
guide wire [Doucette et al 1992]. In addition, cross-sectional area of the coronary 
vessel can be estimated using quantitative coronary angiography (QCA) allowing 
calculation of coronary blood flow [De Feyter et al 1991; Newby 2000]. Bolus 
injection of drugs enables precise and selective coronary administration. The 
injection itself causes an instantaneous increase in blood flow velocity, due to flow-
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mediated dilatation. However this effect is transient and can usually be distinguished 
from true drug responses by avoiding prolonged injections or large volume boluses 
and comparing drug effects with control saline injections [Newby 2000].  
 
Direct measurement of left ventricular pressures during drug administration permits 
assessment of both cardiac loading conditions and the force of left ventricular 
systolic contraction. This can be achieved by placement of a pressure wire within the 
left ventricular cavity [Duckett et al 2011; Ginks et al 2011]. The pressure wire is a 
fine-calibre (0.014-inch) high-fidelity wire that has a torque similar to an angioplasty 
wire [Blows and Redwood 2007]. There is a pressure sensor located 30 mm from its 
tip that can be used to record intraventricular pressure with a frequency response of 
400 Hz. Continuous measurement of left ventricular pressure over the cardiac cycle 
allows calculation of dP/dtmax during isovolumic contraction, a measure of the force 
of left ventricular contraction [Rahimtoola 1973]. In addition, LVEDP and maximum 
left ventricular systolic pressure (LV max) serve as indices of preload and afterload 
respectively. As dP/dtmax is sensitive to changes in preload, afterload and heart rate, 
it does not provide an index of intrinsic myocardial contractility. However this 
limitation can, to some extent be overcome by direct intracoronary drug 
administration which serves to minimise systemic vascular changes. 
 
2.1.4   THORACIC ELECTRICAL BIOIMPEDANCE 
Thoracic electrical bioimpedance (TEB) cardiography is a non-invasive method of 
assessing cardiac output [Woltjer et al 1997]. The technique uses changes in thoracic 
electrical impedance to measure changes in the duration of cardiac ejection, and the 
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velocity of blood flow within the aorta. Four dual sensors are placed on either side of 
the neck and thorax. The outer sensors transmit a constant, low-amplitude alternating 
electrical current to the thorax. The corresponding voltage is detected by the inner 
sensors and used to determine thoracic impedance, according to Ohm’s law. After 
filtering of the respiratory component, changes in impedance predominantly reflect 
changes in the volume and velocity of blood in the aorta during systole and diastole.  
 
Thoracic electrical bioimpedence has been validated against thermodilution 
measurements with correlation coefficients ranging from 0.83-0.90 and mean 
differences ranging from 2-12% [Appel et al 1986; Salandin et al 1988; Northridge 
et al 1990; Thomas 1992]. In addition, measures of changes in cardiac output after 
drug intervention are in close agreement with simultaneous thermodilution 
measurements [Thomas 1992]. The safety and reproducibility of the bioimpedance 
technique makes it a suitable method for studies of drug action [Haynes et al 1993]. 
 
2.2 STUDY PARTICIPANTS AND CONDITIONS 
 
2.2.1   ETHICAL CONSIDERATIONS 
All studies were performed with the approval of the local Research Ethics 
Committee, in accordance with the Declaration of Helsinki, and with the written 





2.2.2   STUDY PARTICIPANTS 
Healthy volunteers and control subjects were not taking any regular medication and 
had no history of any clinically significant medical condition or symptoms of recent 
infective or inflammatory illness.  
 
Patients attending for diagnostic angiography were excluded if they were found to 
have left main stem stenosis or severe coronary artery stenosis, previous coronary 
intervention, and clinical or echocardiographic evidence of cardiac failure.  
 
Patients with heart failure were eligible for inclusion if they had stable NYHA class 
II–IV symptoms, were on maximally tolerated doses of heart failure medication for 
at least 3 months, and had objective evidence of left ventricular impairment (left 
ventricular end-diastolic diameter >5.5 cm and left ventricular ejection fraction 
<40% or shortening fraction <20%). Patients were excluded if they had 
haemodynamically significant valvular heart disease, renal or hepatic failure, or had 
previous malignant ventricular arrhythmias. 
 
2.2.3   SUBJECT PREPARATION 
All studies were carried out in a quiet, temperature-controlled room (22-25°C). 
Participants were semi-recumbent (venous studies) or supine and had abstained from 
alcohol for 24 hours, and from food and caffeine-containing drinks for at least 
4 hours before the study. Healthy volunteers and controls avoided vasoactive and 
non-steroidal anti-inflammatory drugs for 7 days prior to studies and patients with 
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heart failure withheld their usual medications on the day of the study until 
completion of the study protocol. 
 
2.2.4   BLOOD PRESSURE AND HEART RATE MONITORING 
Heart rate and blood pressure were monitored continuously by invasive manometry 
during intracoronary studies and at regular intervals throughout all other studies with 
a semi-automated, non-invasive oscillometric sphygmomanometer (HEM 705CP; 
Omron, Tokyo, Japan). 
 
2.3 DRUGS AND MATERIALS 
 
2.3.1   DRUGS 
The effects of apelin agonism were assessed using synthetic pharmaceutical grade 
apelin-36 and (Pyr1)apelin-13 (Clinalfa AG, Läufelfingen, Switzerland). Biological 
activity of the peptides was established by confirmation of depressor responses in 
rats (n=4; data on file).  
 
Preconstriction of dorsal hand veins was achieved by norepinephrine (Hospira, IL, 
USA). Sodium nitroprusside (SNP; Mayne Pharma Plc, Warwickshire, UK), 
glyceryl trinitrate (GTN; UCB Pharma, Slough, UK) and acetylcholine (Novartis 
Pharmaceuticals UK Ltd, Frimley, UK) were employed in regional infusion studies 
as control vasodilators. Endogenous nitric oxide production was inhibited with               
L-NG-monomethyl-arginine (L-NMMA; Clinalfa AG, Läufelfingen, Switzerland). 
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Cycloxygenase inhibition was achieved by a single 600 mg dose of dispersible 
aspirin (Aspar Pharmaceuticals Ltd, London, UK), dissolved in carbonated water. 
 
All infused drugs were administered following dissolution in 0.9% physiological 
saline (Baxter Healthcare Ltd, Thetford, Norfolk, UK) under aseptic conditions on 
the day of the study. 
 
2.4 DORSAL HAND VEIN STUDIES  
 
2.4.1   INTRAVENOUS ADMINISTRATION 
A 23-gauge butterfly cannula (Smiths Medical International, Watford, UK) was 
inserted into a non-branching dorsal hand vein of the non-dominant arm in the 
direction of flow and attached to a 16-gauge epidural catheter (Portex Ltd, Hythe, 
UK). Patency was maintained by infusion of saline via an IVAC P6000 syringe 
pump (Alaris Products, Basingstoke, UK). The total rate of intravenous infusions 
was maintained constant throughout all studies at 0.25 mL/min.  
 
2.4.2   DORSAL HAND VEIN MEASUREMENT 
The hand was supported above the level of the heart by means of an arm rest and an 
upper arm cuff inflated to 40 mmHg to obstruct venous return [Aellig 1981] as 
shown in Figure 2.1. A magnetised lightweight rod was rested on the summit of the 
infused vein, 1 cm downstream from the tip of the infusion needle. The rod was 
passed through the core of a LVDT (Model 025 MHR, Lucas Schaevitz Inc, 
Pennsauken, NJ, USA), supported above the hand by a small tripod (Figure 2.1). 


























Vertical displacement of the rod following transient cuff deflation causes a linear 
change in the voltage generated by the LVDT reflecting changes in the internal 
diameter of the vein. The voltage output from the LVDT was transferred to a 
Macintosh Classic II computer (Apple Computer Inc, Cupertino, CA, USA) using a 
MacLab analogue-to-digital converter (AD Instruments Ltd, Castle Hill, NSW, 
Australia) and Chart™ software (Version 5.4.2, AD Instruments).  
 
2.4.3   DATA ANALYSIS 
Baseline vein diameter was calculated as the mean of the last three measurements 
during the initial infusion of saline, before the start of active drug infusion. The intra-
subject coefficient of variation for between-day measurements was 10.0% for basal 
hand vein diameter and 15.3% for hand vein responses to SNP. In order to minimise 
the effects of inter-subject variability in hand vein diameter, responses to local drug 
infusion are expressed as percentage change in vein diameter from baseline [Haynes 
et al 1994; Gudmundsdóttir et al 2006]. 
 
2.5 FOREARM PLETHYSMOGRAPHY STUDIES 
 
2.5.1   BRACHIAL ARTERY CANNULATION 
Subjects underwent brachial artery cannulation with a 27-standard wire gauge steel 
needle (Cooper's Needle Works Ltd, Birmingham, UK) under 2% lidocaine 
(Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia 






Figure 2.2   Set-up for forearm venous occlusion plethysmography studies.
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and patency maintained by infusion of saline 0.9% via an IVAC P6000 syringe pump. In 
all studies, saline was infused for the first 20 minutes to allow for equilibration and 
the intra-arterial infusion rate remained constant at 1 mL/min. 
 
2.5.2   BLOOD FLOW MEASUREMENT 
Blood flow was measured in the infused and non-infused forearms by venous 
occlusion plethysmography using mercury-in-silastic strain gauges that were applied 
to the widest part of the forearm [Wilkinson and Webb 2001]. During measurement 
periods, the hands were excluded from the circulation by rapid inflation of the wrist 
cuffs to a pressure of 220 mmHg using E20 Rapid Cuff Inflators (DE Hokanson Inc, 
WA, USA). Upper arm cuffs were inflated intermittently to 40 mmHg pressure for 
10 seconds in every 15 seconds to achieve venous occlusion and obtain 
plethysmographic recordings. Analogue voltage output from an EC-4 strain gauge 
plethysmograph (DE Hokanson Inc, WA, USA) was processed by a PowerLab 
analogue-to-digital converter and Chart™ software (version 5.0.1, AD Instruments) 
and recorded onto a Dell Latitude laptop computer (Dell Computers Ltd, UK). 
Calibration was achieved using the internal standard of the plethysmograph.  
 
2.5.3   INHIBITION OF NITRIC OXIDE AND CYCLOOXYGENASE  
Endogenous nitric oxide was inhibited by the use of a ‘nitric oxide clamp’, as 
described previously [Stroes et al 1997]. In brief, the nitric oxide synthase inhibitor 
L-NMMA was continuously infused (8 µmol/min) to achieve maximal inhibition of 
local nitric oxide synthesis [Vallance et al 1989; Calver et al 1992;                     
Stroes et al 1995]. After 20 minutes of L-NMMA infusion, when steady state blood 
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flow was obtained, SNP, an exogenous nitric oxide donor, was co-infused in 
incremental doses (90-900 ng/min) and titrated to restore baseline FBF. L-NMMA 
and SNP were then co-infused, at these rates, for the remainder of the study; thus 
allowing simulation of normal basal nitric oxide activity during continuous inhibition 
of endogenous nitric oxide synthesis [Honing et al 2000; Ueda et al 2004].  
 
Inhibition of the cyclooxygenase enzyme and thus the production of prostaglandins 
and thromboxanes was achieved by a single dose of dispersible aspirin (600 mg), 
dissolved in carbonated water and administered orally 30 minutes before study 
commencement. This dose of aspirin rapidly inhibits bradykinin-stimulated 
endothelial production of prostacyclin by at least 85% with recovery developing over 
the next 6 hours [Heavey et al 1985]. 
 
2.5.4   DATA ANALYSIS 
Plethysmographic data were extracted from the Chart™ data files (Figure 2.3) and 
FBF was calculated for individual venous occlusion cuff inflations by use of a 
template spreadsheet (Microsoft Excel for Mac 2004; Microsoft Corporation, WA, 
USA). Recordings from the first 60 seconds after wrist cuff inflation were not used 
because of the variability in blood flow that this incurs [Benjamin et al 1995]. 
Usually, the last five flow recordings in each 3-minute measurement period were 
calculated and averaged for each arm. The non-infused arm acted as a 




























Figure 2.3 Typical plethysmographic traces 
 
FBF infused arm: baseline 
FBF non-infused arm: baseline  
FBF infused arm: SNP 4µg/min 
FBF non-infused arm: SNP 4µg/min 
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The effect of the nitric oxide clamp and aspirin on FBF responses to (Pyr1)apelin-13 
and acetylcholine were assessed by calculating area under the curve (AUC) during 
drug infusions using the trapezoid method.  
 
Analysis of all data collected during the forearm plethysmography study was 
undertaken by a single operator in a blinded fashion. Forearm blood flow responses 
are reported as absolute blood flow responses (mL/100 mL tissue/min) in the infused 
and non-infused arm. The intra-subject coefficient of variation for between-day 
measurements was 11.7% for baseline FBF and 16.3% for blood flow responses to 
apelin-36. 
 
2.6 CORONARY AND CARDIAC STUDIES 
 
2.6.1   CARDIAC CATHETERISATION 
Following diagnostic coronary angiography and intravenous administration of 
unfractionated heparin (5000 units), a coronary guide catheter was engaged in the 
ostium of the left coronary artery and a 0.014-inch 12.5 MHz Doppler wire (FloWire, 
Cardiometrics Inc, Mountain View, CA, USA) positioned in the coronary artery to 
measure blood flow velocity. A further catheter was inserted into the left ventricle 






2.6.2   MEASUREMENT OF CORONARY BLOOD FLOW 
Coronary angiography was performed, immediately prior to, and 30 seconds after, 
each drug bolus. Blood flow velocity was determined using the average peak 
velocity of the Doppler signal [Newby et al 2001]. 
 
2.6.3   MEASUREMENT OF LEFT VENTRICULAR PRESSURE 
The output from the pressure wire was connected to a Radi analyzer® and connected 
to a computer with PhysioMon® software to give curves showing real-time blood 
pressure and left ventricular dP/dtmax.  
 
2.6.4   DATA ANALYSIS 
Coronary luminal diameter was measured by quantitative computerised analysis with 
an automated edge contour detection analysis system from end-diastolic frames of 
each angiogram and cross-sectional area calculated assuming circular geometry 
[Newby et al 2001]. The stem of the coronary catheter was used for calibration to 
determine absolute measurement in millimetres, and correction. Coronary blood flow 
was defined as half the product of the average peak velocity and the cross-sectional 
area of the coronary artery [Newby et al 2001]. Ten-second samples of pressure 
recordings within the left ventricle were taken before and at 60 seconds after each 
drug bolus and used to calculate dP/dtmax, LV max and LVEDP. For within-day 
measurements, the intra-subject coefficient of variation was 13.0% for coronary 




2.7 SYSTEMIC HAEMODYNAMIC STUDIES 
 
2.7.1   INTRAVENOUS ADMINISTRATION 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the 
antecubital fossae of both arms to allow drug infusion and sampling of venous blood. 
The rate of infusion was kept constant at 1 mL/min throughout all studies. 
 
2.7.2   MEASUREMENT OF SYSTEMIC HAEMODYNAMIC VARIABLES 
Cardiac output was measured using a TEB monitor (Modular HOTMAN® System 
with EXT-TEBCO® Module, HemoSapiens Inc, CA, USA), following 
manufacturer’s guidelines. The EXT-TEBCO® Module was attached via a USB 
cable to a Dell Latitude laptop computer (Dell Computers Ltd, UK) installed with 
HOTMAN® software. After preparing the skin with alcohol to to ensure good 
adhesion and low skin-to-electrode impedance, EXT-TEBCO® Module was 
connected to the patients via four pairs of low contact impedance electrodes 
[Northridge et al 1990] (Figure 2.4). The lower thoracic voltage sensing electrodes 
placed at the level of the xiphoid sternum in the midaxillary lines and the cervical 
sensing electrodes were positioned laterally at the base of the neck as close as 
possible to the clavicles. The ‘current injecting’ electrodes delivered an alternating 
current of 7 µA at 65 kHz and were placed with one pair 5 cm above the cervical 











Figure 2.4  TEBCO module and electrodes connected to laptop computer. 
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The EXT-TEBCO® Module estimated stroke volume from the impedance signal 
recorded from the inner pairs of electrodes using the Sramek-Bernstein equation 
[Bernstein et al 1986]. 
 
SV = VEPT x VET x (dz/dt)max/ZO 
Where VEPT=volume of electrically participating tissue (a constant derived from 
body height and weight); VET=ventricular ejection time; dz/dt=rate of change of 
impedance during systole; and ZO=basal thoracic impedance. 
 
The monitor automatically averages cardiac output over 16 cardiac cycles and 
displays it continuously in real-time. Blood pressure and heart rate were measured 
periodically with a semi-automated non-invasive oscillometric sphygmomanometer 
(HEM 705CP; Omron, Tokyo, Japan) and values entered manually via the laptop 
keyboard.  
 
2.7.3   DATA ANALYSIS 
At each time point, cardiac output was recorded manually from the continuous 
monitor display as the mean of three recordings, each recording representing the 
average of 16 consecutive heartbeats [Northridge et al 1990]. Cardiac output was 
corrected for body surface area to give cardiac index. Mean arterial pressure was 
defined as the sum of the diastolic blood pressure and a third of the pulse pressure. 
Peripheral vascular resistance index was calculated as mean arterial pressure divided 
by cardiac index and expressed in dyne.s/cm5/m2. For between-day measurements of 
cardiac output, the coefficient of variation was 6.4%. 
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2.8 BLOOD SAMPLING AND ASSAYS 
 
Blood samples (10 mL) were drawn by a single venepuncture or repeatedly via a 
venous cannulae (17-gauge) inserted into a large subcutaneous vein of the 
antecubital fossa into tubes containing either ethylene diamine tetraacetic acid 
(EDTA) or lithium heparin, and kept on ice before centrifugation at 2000 g for 
30 minutes at 4°C. Platelet-free plasma was decanted and stored at -80°C before 
assay.  
 
Plasma apelin-36 concentration was measured using the apelin-12 micro-plate 
enzyme-linked immunosorbent assay (ELISA) kit (Phoenix Europe GmbH, 
Karlsuhe, Germany). The antibody used in this assay has 100% cross-reaction with 
apelin-12, apelin-13 and apelin-36 but cross-reaction with (Pyr1)apelin-13 is 
unknown. The minimal detectable apelin concentration with this assay is 
0.07 ng/mL. The intra-assay coefficient of variation was 9% and the inter-assay 
coefficient of variation <15%. 
 
Plasma renin activity was measured under standard conditions through the generation 
of angiotensin I as determined by radioimmunoassay (DiaSorin Ltd, Wokingham, 
UK) [Haber et al 1969]. Plasma brain natriuretic peptide (BNP) and 
AVP concentrations were measured by immunoradiometric assay (Shionogi and Co 
Ltd, Osaka, Japan) and direct radioimmunoassay (Bühlmann Laboratories AG, 
Schonebuch, Switzerland) respectively. The intra- and inter-assay coefficients of 
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variation for plasma renin activity, BNP and AVP were 7.3% and 6.7%; 2.7% and 




Data were examined by analysis of variance (ANOVA) with repeated measures and 
two-tailed paired Student's t-test as appropriate using GraphPad Prism (GraphPad 
Software, Inc, CA, USA). All results are expressed as mean ± standard error of the 












DIRECT VASCULAR ACTIONS OF APELIN  
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Vascular effects of apelin in vivo in man.  





In preclinical models, apelin causes arterial and venous vasodilatation and is the 
most potent inotrope yet described. We aimed to establish the direct in vivo vascular 
effects of apelin in man. Vascular effects of apelin were assessed in 14 healthy 
volunteers and 6 patients undergoing diagnostic coronary angiography. Dorsal hand 
vein diameter was measured by the Aellig technique during local intravenous 
infusions of apelin-36 and (Pyr1)apelin-13 (0.1-3 nmol/min) and SNP 
(0.6 nmol/min). Forearm blood flow was measured by venous occlusion 
plethysmography during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 
(0.1-10 nmol/min). Coronary blood flow was measured by Doppler flow wire and 
QCA following intracoronary boluses of apelin-36 (20 and 200 nmol in 2 mL), 
0.9% saline (2 x 2 mL) and GTN (100 µg in 2 mL). Although SNP caused 
venodilatation (P<0.0001), apelin-36 and (Pyr1)apelin-13 had no effect on dorsal 
hand vein diameter (P=0.2). Both apelin-36 and (Pyr1)apelin-13 caused 
vasodilatation in forearm resistance vessels (P<0.0001). Intracoronary bolus of 
apelin-36 increased coronary blood flow (P<0.05). Although having no apparent 
effect on venous tone, acute apelin administration in man causes peripheral and 
coronary vasodilatation. The apelin system merits further clinical investigation to 








Apelin was identified in 1998 [Tatemoto et al 1998] as the endogenous ligand for the 
then orphan G-protein coupled receptor, APJ [O’Dowd et al 1993], now renamed the 
‘apelin receptor’ [Pitkin et al 2010a]. The apelin gene encodes a 77 amino acid 
prepropeptide that undergoes proteolytic cleavage to yield bioactive peptides of 
variable length: 13, 17 and 36 amino acids [Tatemoto et al 1998; Habata et al 1999; 
Hosoya et al 2000]. The shorter isoforms have greater affinity for the apelin receptor 
[Hosoya et al 2000; Masri et al 2006] and more potent cardiovascular effects in 
preclinical models [Tatemoto et al 2001], particularly the pyroglutamated form of 
apelin-13, (Pyr1)apelin-13. Widely expressed in the CNS and peripheral tissues [De 
Mota et al 2000; Hosoya et al 2000; Kawatama et al 2001; De Falco et al 2002], the 
apelin system participates in a diverse array of processes including glucose 
metabolism [Sorhede et al 2005], food intake [Sunter et al 2003], thermoregulation 
[Jaszberenyi et al 2004] and fluid balance [De Mota et al 2004]. However, its 
principal physiological role appears to relate to its cardiovascular actions.  
 
Apelin receptors are present on endothelial cells and vascular smooth muscle cells 
[Kleinz et al 2005], and in preclinical models, apelin signalling exerts major effects 
on vascular tone. In rodent models, exogenous apelin administration causes a rapid 
fall in arterial blood pressure [Reaux et al 2001; Tatemeoto et al 2001; El Messari et 
al 2004; Ishida et al 2004; Lee et al 2005] mediated by nitric oxide [Tatemoto et al 
2001] and a concomitant reduction in mean capillary filling pressure [Cheng et al 
2003], indicating powerful vasodilator and venodilator effects. To date, there have 
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been no in vivo clinical studies but ex vivo myography studies report that apelin 
causes a nitric oxide-dependent vasorelaxation in human mesenteric artery [Salcedo 
et al 2007] and venoconstriction in endothelium-denuded human saphenous vein 
[Katugampola et al 2001].  
 
Apelin is emerging as an important mediator of cardiovascular homeostasis, yet its 
cardiovascular actions in vivo in man are unknown. Detailed clinical investigation to 
establish the role of the apelin system in human cardiovascular regulation is an 
essential prerequisite to elucidating its pathophysiological relevance and therapeutic 
potential. As a first step towards characterising the in vivo cardiovascular profile of 
apelin in man, we sought to determine its direct vasomotor effects in the peripheral 




3.3.1   SUBJECTS 
Fourteen healthy volunteers aged between 19 and 24 years and six patients attending 
for elective outpatient diagnostic coronary angiography participated in these studies, 
which were performed with the approval of the local Research Ethics Committee, in 
accordance with the Declaration of Helsinki, and with the written informed consent 
of all subjects. Healthy volunteers were not taking any regular medication and had no 
history of any clinically significant medical condition or symptoms of recent 
infective or inflammatory illness. Patients attending for diagnostic angiography were 
excluded if they were found to have left main stem stenosis or severe coronary artery 
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stenosis, previous coronary intervention, and clinical or echocardiographic evidence 
of cardiac failure. Patients withheld their usual medications on the day of the study 
until completion of the study protocol and all participants abstained from alcohol for 
24 hours and from food and caffeine-containing drinks for at least 4 hours before 
each study.  
 
3.3.2   DRUGS 
The effects of apelin receptor agonism were assessed using synthetic 
pharmaceutical grade apelin-36 and (Pyr1)apelin-13. The doses of apelin peptides 
were chosen to achieve end-organ concentrations equivalent to systemic 
concentrations generated in preclinical in vivo studies (assuming a dorsal hand vein 
flow of 1-5 mL/min, brachial artery blood flow of 25 mL/min and coronary artery 
blood flow of 125 mL/min) and based on preliminary exploratory forearm 
plethysmography studies employing doses from 0.0001-10 nmol/min (n=6; data not 
shown).  
 
3.3.3   MEASUREMENTS 
All studies were carried out in a quiet, temperature-controlled room (22-25°C). 
Participants were semi-recumbent (venous studies) or supine (peripheral and 
coronary arterial studies) Heart rate and blood pressure were monitored at regular 
intervals throughout peripheral venous and arterial studies with a semi-automated, 





A 23-gauge needle was sited in a non-branching dorsal hand vein in the direction of 
flow and the total infusion rate was kept constant at 0.25 mL/min. The hand was 
supported above the level of the heart and an upper arm cuff inflated to 40 mmHg to 
obstruct venous return. The internal diameter of the dorsal hand vein was measured 
by the Aellig technique [Aellig 1981]. Briefly, a magnetised lightweight rod was 
rested on the summit of the infused vein, 1 cm downstream from the tip of the 
infusion needle. The rod was passed through the core of a LVDT, supported above 
the hand by a small tripod. Changes in vein diameter caused vertical displacement of 
the rod, leading to a linear change in the voltage generated by the LVDT, thus 
enabling calculation of absolute changes in vein size. 
 
Peripheral Arterial Studies 
Subjects underwent brachial artery cannulation with a 27-standard wire gauge steel 
needle under controlled conditions. In all studies, saline was infused for the first     
20 minutes to allow for equilibration and the intra-arterial infusion rate remained 
constant at 1 mL/min. Forearm blood flow was measured in the infused and non-
infused forearms by venous occlusion plethysmography using mercury-in-silastic 
strain gauges as described previously [Newby et al 1997a; Newby et al 1999]. 
 
Coronary Artery Studies  
Following diagnostic coronary angiography, a coronary guide catheter was engaged 
in the ostium of the left coronary artery and a 0.014-inch 12.5 MHz Doppler wire 
positioned in the coronary artery to measure blood flow velocity. Additionally, as 
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described in Chapter 5, a further catheter was inserted into the left ventricle and a 
0.014-inch pressure wire placed in the left ventricular cavity to measure left 
ventricular pressures. Coronary angiography was performed, immediately prior to, 
and 30 seconds after, each drug bolus. Coronary luminal diameter was measured by 
quantitative computerised analysis with an automated edge contour detection 
analysis system from end-diastolic frames of each angiogram and cross-sectional 
area calculated assuming circular geometry [Newby et al 2001]. Blood flow velocity 
was determined using the average peak velocity of the Doppler signal [Newby et al 
2001]. Coronary blood flow was defined as half the product of the average peak 
velocity and the cross-sectional area of the coronary artery [Newby et al 2001]. 
 
3.3.4   STUDY PROTOCOL 
Protocol 1: Effects of apelin receptor agonism on venous tone 
Because the dorsal hand vein does not have basal resting tone, norepinephrine         
(1-32 ng/min) was infused to induce and maintain a 50-70% reduction in vein 
diameter. Six subjects then received incremental intravenous infusions (0.1, 0.3, 1, 
3 nmol/min) of either (Pyr1)apelin-13 or apelin-36 for 8 minutes at each dose 
followed, after a 20-minute washout period, by a single 8-minute dose of the control 
venodilator, SNP at 0.6 nmol/min. To ensure that norepinephrine was not masking 
constrictor effects, a further three subjects received the same doses of (Pyr1)apelin-13 
and apelin-36 in the absence of norepinephrine preconstriction. 
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Protocol 2: Effects of apelin receptor agonism on forearm resistance vessel tone 
Five subjects attended on two occasions at least one week apart and received either 
apelin-36 or (Pyr1)apelin-13 at sequential doses of 0.1, 0.3, 1, 3, and 10 nmol/min for 
10 minutes at each dose followed by a single 10-minute saline washout.  
 
Protocol 3: Coronary artery and myocardial contractility studies 
In a double-blind randomised cross-over manner, intracoronary boluses of apelin-36 
(20 and 200 nmol in 2 mL) and 0.9% saline (2 x 2 mL) followed by a single-blinded 
non-randomised bolus of GTN (100 µg in 2 mL) were administered in six subjects 
via the coronary guide catheter. All drug boluses were followed by a 2 mL 0.9% 
saline flush and 5-minute washout intervals were allowed between drugs. Coronary 
blood flow was calculated before and after each drug bolus as described above.  
 
3.3.5   DATA AND STATISTICAL ANALYSES 
Dorsal hand vein [Haynes et al 1995], forearm plethysmographic [Newby et al 
1997a] and coronary blood flow [Newby et al 2001] data were analysed in a blinded 
fashion as described previously. Variables are reported as mean ± SEM and analysed 
using repeated measures ANOVA with post-hoc Bonferroni corrections and two-









In all studies, apelin was well tolerated with no significant adverse events. There 
were no changes in heart rate or blood pressure during intravenous or intrabrachial 
apelin infusions. 
 
Protocol 1: Effects of apelin on peripheral venous tone 
Neither (Pyr1)apelin-13 nor apelin-36 caused venoconstriction in relaxed dorsal hand 
veins (data not shown). Following stable preconstriction with norepinephrine 
(Figure 3.1), dorsal hand vein diameter was unaffected by (Pyr1)apelin-13 or    
apelin-36 (P=0.2) but was increased by SNP.  
 
Protocol 2: Effects of apelin on forearm resistance vessel tone 
Both (Pyr1)apelin-13 and apelin-36 increased blood flow in the infused arm  
(P<0.0001; Figure 3.2). Whilst the magnitude of the vasodilator response did not 
differ between the two isoforms (P>0.05, ANOVA) blood flow appeared to plateau 
at doses of apelin-36 >0.1 nmol/min, but continued to increase with (Pyr1)apelin-13 
infusion up to the peak dose of 10 nmol/min. Following 10 minutes of saline 
washout, blood flow was unchanged with apelin-36 but appeared to decline with 
(Pyr1)apelin-13 (P<0.05, ANOVA; data not shown). In the non-infused arm there 
was no change in blood flow during apelin-36 infusion but a small increase at the 
maximum dose of 10 nmol/min during (Pyr1)apelin-13 infusion.  
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Figure 3.1  DHV diameter during co-infusion of norepinephrine and A: incremental doses of 
(Pyr1)apelin-13 (!) and single dose of SNP ("; 0.6 nmol/min); B: incremental doses of apelin-36 
(#) and single dose of SNP (!; 0.6 nmol/min). ***P<0.001, paired student’s t-test.  















































































Figure 3.2  Forearm blood flow in the infused (!) and non-infused arm (#) during infusion of apelin 
peptides. For dose-responses to (Pyr1)apelin-13 and apelin-36 in the infused arm: P<0.001, one-way 
ANOVA. *P<0.05, **P<0.01, ***P<0.001, post-hoc Bonferroni tests versus baseline.  
ANOVA - analysis of variance. 
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Coronary Blood Flow  
Patients were aged 60 ± 4 years and five were male. All patients had near normal 
coronary arteries with no haemodynamically significant flow limiting stenoses 
(<25% luminal stenosis).  
 
Left ventricular pressure measurements are reported in Chapter 5. There were no 
significant changes in coronary blood flow following injection of 20 nmol apelin-36 
(data on file). Compared with saline placebo, there was an increase in coronary blood 
flow following intracoronary administration of 200 nmol apelin-36 and a trend 
toward an apparent increase with GTN which did not reach statistical significance 
(Figure 3.3). In comparison with placebo, GTN caused a fall in mean arterial 
pressure (94 ± 8 versus 80 ± 9 mmHg, P<0.01) and rise in heart rate (67 ± 5 versus 
69 ± 5 bpm, P<0.001) but apelin had no effect on blood pressure 










































































Figure 3.3  Coronary blood flow, average peak velocity of blood and epicardial coronary artery 
diameter following bolus injection of apelin-36 (200 nmol), GTN (100 µg) and 0.9% saline. *P<0.05, 
†P=0.07, paired student’s t-test versus 0.9% saline. 
GTN - glyceryl trinitrate. 
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3.5    DISCUSSION 
 
This is the first study to examine the in vivo vascular actions of apelin in man. Using 
robust well-validated techniques, we have assessed the direct effects of two 
endogenous apelin peptides on vascular tone. Whilst not affecting peripheral venous 
tone, apelin peptides cause vasodilatation in peripheral resistance vessels and the 
coronary arterial circulation.  
 
3.5.1   EFFECTS OF APELIN ON PERIPHERAL ARTERIOLAR TONE 
In keeping with preclinical models and studies of human mesenteric vessels in vitro, 
we have demonstrated that apelin causes vasodilatation in human forearm resistance 
vessels in vivo. We studied two different apelin isoforms: apelin-36, the full-length 
mature peptide, and (Pyr1)apelin-13, a shorter C-terminal fragment. Although shorter 
apelin peptides are reported to have more potent depressor activity in rats    
[Tatemoto et al 2001], we saw no apparent difference in the overall vasodilator 
response to these two isoforms. However, whilst the response to (Pyr1)apelin-13 
appeared to be dose-dependent, vasodilatation to apelin-36 plateaued from an early 
stage. Rapid desensitisation of responses to apelin have previously been 
demonstrated in vitro, particularly with apelin-36 [Masri et al 2006], most likely due 
to depletion of cell surface receptors following internalisation. However further 
dedicated in vivo studies will be required to distinguish this possibility from a true 
ceiling of vasodilator response. We measured changes in FBF during local 
intrabrachial apelin infusions with the non-infused arm serving as a 
contemporaneous control. The slight increase in blood flow in the non-infused arm 
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during infusion of the maximum dose of (Pyr1)apelin-13 raises the possibility of 
spillover of infused apelin into the systemic circulation. However no increase in non-
infused arm blood flow was seen during apelin-36 infusion and there were no 
changes in heart rate or blood pressure with either apelin isoform. Measurement of 
systemic plasma apelin concentrations during local dose infusions would help to 
clarify the threshold dose for systemic spillover. 
 
3.5.2   EFFECTS OF APELIN ON CORONARY BLOOD FLOW 
In keeping with its effects in peripheral resistance vessels, we have demonstrated that 
apelin is a direct coronary vasodilator. Concordance between vasomotor responses in 
the forearm and other vascular beds is generally good [Wilkinson and Webb 2001], 
but differences do exist. Additionally, apelin has been shown to exert direct 
vasoconstrictor effects in isolated human vessels ex vivo [Katugampola at al 2001]. 
Given the potentially deleterious consequences of coronary vasoconstriction in 
conditions such as heart failure, establishing the in vivo effects of apelin on coronary 
blood flow in man is therefore an essential prerequisite to exploring its therapeutic 
application.  
 
Following intracoronary administration of apelin there was an increase in coronary 
blood flow compared with saline placebo. The finding that the average peak velocity 
of blood flow increased without any concurrent change in epicardial diameter could 
be interpreted as indicating a predominant action of apelin on resistance rather than 
conductance vessels However, given the small sample size and relative lack of 
sensitivity of QCA [Newby et al 2000] for detecting small changes in lumen size, it 
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is perhaps likely that our study was underpowered to detect a significant change. In 
keeping with this we also observed no significant change in epicardial coronary 
diameter with GTN, an agent well known to cause dilatation of coronary 
conductance arteries [Hood et al 1980]. We employed only two doses of apelin and 
measured blood flow responses at a single time point following bolus injection, 
observing an increase only at the higher dose. Further studies will be required to 
characterise the dose-response relationship and time course of apelin-mediated 
coronary vasodilatation. Another important limitation of this study is that all of our 
subjects were free of significant obstructive coronary artery disease. Other 
endothelium-dependent vasodilators such as acetlychoine have previously been 
shown to exert paradoxical vasoconstriction in coronary arteries with a heavy 
atherosclerotic burden [Ludmer et al 1986]. Like acetylcholine, apelin causes 
vasconstriction in ex vivo myography studies when vessels are denuded of 
endothelium [Katugampola et al 2001]. The direct coronary effects of apelin in 
patients with significant coronary artery disease and other conditions associated with 
endothelial dysfunction will therefore require further study. 
 
3.5.3   EFFECTS OF APELIN ON PERIPHERAL VENOUS TONE 
Preclinical studies examining the venous effects of apelin have produced conflicting 
results. Apelin-13 lowered systemic venous tone in rats suggesting a powerful 
venodilator effect [Cheng et al 2003], but the same apelin fragment caused potent 
venoconstriction in ex vivo endothelium-denuded human saphenous vein. 
[Katugampola et al 2001]. In the present study, local in vivo infusion of apelin-36 or 
(Pyr1)apelin-13 had no effect on either basal or preconstricted dorsal hand vein 
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diameter. We demonstrated constrictor and dilator responses to norepinephrine and 
SNP respectively, and employed doses of apelin 10-fold higher than those required 
to cause vasodilatation in the forearm arterial circulation. It is therefore unlikely that 
the lack of venous response to apelin reflected either inadequate dosing or sensitivity 
of the technique. It should be noted, however, that we have examined the effects of 
apelin in a single peripheral venous bed. We cannot exclude the possibility that 
apelin may exert a direct effect on central veins. Further clinical studies are required 
to determine the in vivo effects of apelin in specific venous beds and on systemic 
venous tone. Finally, apelin has been shown to inhibit angiotensin II-induced 
venoconstriction in rat portal vein [Gurzu et al 2006]. While we observed no direct 
effect of apelin on peripheral venous tone, it remains to be determined whether 
apelin modulates the venomotor response to other signalling systems in man, in 
particular the renin-angiotensin-aldosterone system. 
 
3.5.4   CONCLUSIONS 
We have shown that acute apelin administration in vivo in man causes peripheral and 
coronary arterial vasodilation but does not appear to affect peripheral venous tone. 
Increasing evidence suggests that apelin mediates important effects on 
cardiovascular homeostasis in preclinical models, including arterial vasodilatation 
and increased cardiac contractility. Our findings provide the strongest evidence to 
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CHARACTERISATION OF APELIN-MEDIATED VASODILATATION 
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4.1    SUMMARY 
 
We recently demonstrated that apelin causes coronary and peripheral arterial 
vasodilatation in vivo in man. We here aimed to characterise the vasodilator 
responses to two apelin peptides in vivo in the human forearm arterial circulation. 
Vascular effects of apelin were assessed in 16 healthy volunteers. Forearm blood 
flow was measured by venous occlusion plethysmography during intrabrachial 
infusions of apelin-36 and (Pyr1)apelin-13 (0.1-30 nmol/min) and subsequently in the 
presence or absence of a nitric oxide clamp (NO synthase inhibitor,                          
L-NMMA (8 µmol/min), co-infused with SNP (90-900 ng/min)), or a single oral 
dose of aspirin (600 mg) or matched placebo. Both apelin-36 and (Pyr1)apelin-13 
caused reproducible vasodilatation in forearm resistance vessels (P<0.0001) with a 
rapid onset and prolonged offset. Plasma apelin concentrations and blood flow in the 
non-infused arm (P<0.05) were increased at doses >3 nmol/min, consistent with 
systemic spillover. At subsystemic doses, the two apelin isoforms elicited equivalent 
vasodilatation. Continuous infusion of (Pyr1)apelin-13 for 42 minutes elicited 
sustained, near maximal vasodilatation. (Pyr1)apelin-13-mediated vasodilatation was 
attenuated by the nitric oxide clamp (P=0.004) but was unaffected by aspirin (P=0.7). 
Apelin causes nitric oxide-dependent arterial vasodilatation in vivo in man. The 
apelin system merits further clinical investigation to determine its role in 







Apelin is the endogenous ligand [Tatemoto et al 1998] for the previously ‘orphan’ 
G-protein coupled receptor, APJ [O’Dowd et al 1993], now renamed the ‘apelin 
receptor’ [Pitkin et al 2010a] The full-length mature apelin peptide comprises 
36 amino acids (apelin-36) but a 13 amino acid fragment of its C-terminus has also 
been detected in vivo and exhibits biological activity [Hosoya et al 2000]. This 
fragment undergoes a pyroglutamate substitution at its N-terminus in vivo 
((Pyr1)apelin-13), likely rendering it more resistant to enzymatic cleavage 
[Kleinz and Davenport 2005]. The distinct physiological roles of these two different 
apelin peptides and the principal endogenous ligand remains uncertain: (Pyr1)apelin-
13 is the more abundant isoform in cardiac tissue and plasma [Maguire et al 2009], 
exhibits greater affinity for the apelin receptor [Hosoya et al 2000, Masri et al 2006] 
and is more potent than apelin-36 in competitive inhibition assays [Hosoya et al 
2000]; however apelin-36 predominates in bovine colostrum [Hosoya et al 2000], is 
less readily displaced from its receptor [Hosoya et al 2000; Masri et al 2006] and has 
more sustained biological effects [Hosoya et al 2000; Masri et al 2006]. 
 
Apelin receptors are present on endothelial and vascular smooth muscle cells [Kleinz 
et al 2005] and, in preclinical models, apelin signalling exerts major effects on 
vascular tone. In ex vivo myography studies, apelin causes nitric oxide-dependent 
vasorelaxation in human mesenteric arteries [Salcedo et al 2007] and 
venoconstriction in endothelium-denuded human saphenous veins [Katugampola et 
al 2001]. In rodent models, exogenous apelin administration causes a rapid fall in 
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arterial blood pressure [Reaux et al 2001; Tatemeoto et al 2001; El Messari et al 
2004; Ishida et al 2004; Lee et al 2005] mediated by nitric oxide [Tatemoto et al 
2001] and a concomitant reduction in mean capillary filling pressure [Cheng et al 
2003] indicating powerful vasodilator and venodilator effects. 
 
As a first step towards characterising the in vivo cardiovascular profile of apelin in 
man, we recently explored the direct vascular actions in man of apelin-36 and 
(Pyr1)apelin-13. Whilst neither isoform induced alterations in peripheral venous tone, 
both apelin-36 and (Pyr1)apelin-13 caused vasodilatation in forearm resistance 
vessels and the coronary arterial circulation. In this series of studies we sought to 
characterise and compare peripheral vasodilator responses to arterial administration 
of two different apelin isoforms within the forearm vascular bed of healthy 
volunteers and to establish the contribution of the endothelium-derived vasodilators, 




4.3.1   SUBJECTS 
Sixteen healthy volunteers aged between 20 and 24 years participated in these 
studies, which were performed with the approval of the local Research Ethics 
Committee, in accordance with the Declaration of Helsinki, and with the written 
informed consent of all subjects. Participants were not taking any regular medication 
and had no history of any clinically significant medical condition or symptoms of 
recent infective or inflammatory illness.  
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4.3.2   DRUGS 
The effects of apelin agonism were assessed using synthetic pharmaceutical grade 
apelin-36 and (Pyr1)apelin-13. Endogenous nitric oxide was inhibited by the use of a 
nitric oxide clamp, as described previously [Stroes et al 1997]. In brief, the 
nitric oxide synthase inhibitor L-NMMA was continuously infused (8 µmol/min) to 
achieve maximal inhibition of local nitric oxide synthesis [Vallance et al 1989; 
Calver et al 1992; Stroes et al 1995]. After 20 minutes of L-NMMA infusion, when 
steady state blood flow was obtained, SNP an exogenous nitric oxide donor, was co-
infused in incremental doses (90-900 ng/min) and titrated to restore baseline FBF.    
L-NMMA and SNP were then co-infused, at these rates, for the remainder of the 
study; thus allowing simulation of normal basal nitric oxide activity during 
continuous inhibition of endogenous nitric oxide synthesis. Dispersible aspirin 
(600 mg) was dissolved in carbonated water and administered orally 30 minutes 
before commencement of the study [Heavey et al 1985] to inhibit the 
cyclooxygenase enzyme and thus the production of prostaglandins and 
thromboxanes.  
 
4.3.3   MEASUREMENTS 
All studies were carried out in a quiet, temperature-controlled room (22-25°C). 
Participants were supine and had abstained from alcohol for 24 hours, and from food 
and caffeine-containing drinks for at least 4 hours before the study. Heart rate and 
blood pressure were monitored at regular intervals throughout all studies with a 
semi-automated, non-invasive oscillometric sphygmomanometer  
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Subjects underwent brachial artery cannulation with a 27-standard wire gauge steel 
needle under controlled conditions. In all studies, saline was infused for the first     
20 minutes to allow for equilibration and the intra-arterial infusion rate remained 
constant at 1 mL/min. Forearm blood flow was measured in the infused and non-
infused forearms by venous occlusion plethysmography using mercury-in-silastic 
strain gauges as described previously [Newby et al 1997a; Newby et al 1999]. 
 
Blood Sampling 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the 
antecubital fossae of both arms. Blood samples (10 mL) were drawn simultaneously 
from each arm at baseline, during infusion of each dose of apelin and after              
42 minutes of 0.9% saline infusion, into tubes containing EDTA and kept on ice 
before centrifugation at 2000 g for 30 minutes at 4°C. Platelet-free plasma was 
decanted and stored at -80°C before assay. Plasma apelin concentrations were 
measured during apelin-36 infusion using a commercially available apelin-12 
microplate ELISA Kit. 
 
Effects of apelin-36 and (Pyr1)apelin-13 on forearm resistance vessel tone 
In Protocol 1 (Figure 4.1), eight subjects attended on two occasions at least one week 
apart and received continuous incremental doses of either apelin-36 or (Pyr1)apelin-
13 (0.1-30 nmol/min) for 6 minutes at each dose then, following a 42-minute saline 
infusion, a continuous dose of 1 nmol/min for 42 minutes. In Protocol 2 (Figure 4.1), 





















































































































































































































































































































































































































one week apart and received discontinuous incremental doses of either apelin-36 or 
(Pyr1)apelin-13 (0.1-30 nmol/min) with each dose separated by an 18-minute saline 
infusion. 
 
Contribution of nitric oxide and prostacyclin to apelin-mediated vasodilatation 
In a 2 x 2 factorial design, eight subjects attended on four occasions at least one 
week apart and received, in a randomised order: i) the nitric oxide clamp (see above) 
and oral aspirin, ii) the nitric oxide clamp and oral placebo, iii) saline placebo and 
oral aspirin, iv) saline placebo and oral placebo (Figure 4.1). Aspirin administration 
was performed in a double-blinded manner while the nitric oxide clamp was, for 
practical reasons, performed in a single-blinded manner. On all occasions subjects 
then received sequential infusions of (Pyr1)apelin-13 (0.3, 1, 3 nmol/min) and 
acetylcholine (5, 10, 20 µg/min) in a double-blinded manner for 6 minutes at each 
dose with drugs separated by a 30-minute saline infusion. The order of drug infusion 
was randomised between subjects but kept constant over the four visits for each 
individual subject.  
 
4.3.4   DATA AND STATISTICAL ANALYSES 
Forearm plethysmographic data were analysed in a blinded fashion as described 
previously [Newby et al 1997a]. The effect of the nitric oxide clamp and aspirin on 
FBF responses to (Pyr1)apelin-13 and acetylcholine were assessed by calculating 
AUC during drug infusions using the trapezoid method. Apelin assay values were 
not normally distributed and were therefore log tranformed prior to statistical 
analysis. Variables are reported as mean ± SEM and analysed using 
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repeated measures ANOVA with post-hoc Bonferroni corrections and two-tailed 




In all studies, apelin was well tolerated with no significant adverse events. At the 
highest dose of intra-arterial apelin-36, five subjects experienced a mild patchy non-
pruritic localised erythematous swelling in the infused arm that resolved rapidly on 
cessation of drug infusion. There were no changes in heart rate or blood pressure in 
any of the studies. 
 
Protocols 1 & 2: Characterisation of apelin-mediated peripheral vasodilatation 
(Pyr1)apelin-13 and apelin-36 increased FBF in the infused arm (P<0.0001, 
ANOVA; Figure 4.2). The response to apelin-36 was dose-dependent (r2=0.41, 
P<0.0001) but there was a rapid plateauing of effect with (Pyr1)apelin-13 (r2=0.003, 
P=0.73). At the highest dose of 30 nmol/min, infused FBF was greater during apelin-
36 infusion compared with (Pyr1)apelin-13 infusion (Figure 4.3A; P<0.05). 
 
Where doses were separated by saline washouts (Figure 4.4), blood flow declined 
over 18 minutes after each dose, but did not return to baseline. Following continuous 
incremental dose infusion, FBF declined gradually over 42 minutes with both 
isoforms (Figure 4.2; P<0.0001, ANOVA). With (Pyr1)apelin-13, FBF remained 
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Figure 4.2  Infused FBF in Protocol 1 during infusion of (Pyr1)apelin-13 (!) and apelin-36 ("). One-
way ANOVA with repeated measures. **P<0.01, ***P<0.001, post-hoc Bonferroni tests versus baseline.  






























































































Figure 4.3 Infused FBF A: during incremental infusion of (Pyr1)apelin-13 (!) versus apelin-36 (") in 
Protocol 1; 2-way ANOVA with repeated measures. *P<0.05, post-hoc bonferroni tests. B: during 
incremental infusion of (Pyr1)apelin-13 and apelin-36 in the presence (!) and absence (") of saline 
washouts (for both: P>0.05, 2-way ANOVA with repeated measures). 





































































Figure 4.4  Infused FBF in Protocol 2 during infusion of (Pyr1)apelin-13 (!) and apelin-36 ("). One-
way ANOVA with repeated measures. **P<0.01, ***P<0.001, post-hoc Bonferroni tests versus baseline. 
FBF - forearm blood flow; ANOVA - analysis of variance. 
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with apelin-36, infused FBF remained elevated throughout the washout period 
(P<0.0001).  
 
Forty-two minutes after incremental dose infusion of (Pyr1)apelin-13, a further 
continuous infusion of (Pyr1)apelin-13 at 1 nmol/min elicited a sustained increase in 
infused FBF (P<0.0001). As noted above, infused FBF failed to return to baseline 
following incremental apelin-36 infusion. Subsequently, infused FBF failed to rise 
further during continuous infusion of apelin-36 at 1 nmol/min but remained elevated 
with respect to baseline (P<0.001). The inclusion of 18-minute saline washouts 
between dose escalations (Figure 4.3B) did not affect vasodilatation to either 
(Pyr1)apelin-13 (P=0.68) or apelin-36 (P=0.93).  
 
With both apelin isoforms, FBF increased in the non-infused arm (P<0.0001, 
ANOVA) at 30 nmol/min (P<0.05, post-hoc Bonferroni tests; data not shown). 
Plasma apelin concentrations in the infused arm rose with increasing doses of    
apelin-36 (Figure 4.5; P<0.0001) and increased in the non-infused arm from           
10 nmol/min (P<0.01).  
 
Protocol 3: Contribution of nitric oxide and prostacyclin to apelin-mediated 
vasodilatation 
L-NMMA reduced blood flow in the infused arm (3.48 ± 0.41 - 
2.10 ± 0.17 mL/100 mL/min, P<0.001) but this was restored with SNP co-infusion 
(3.20 ± 0.33 mL/100 mL/min, P>0.05 versus baseline). Both (Pyr1)apelin-13 
 97 
 

















Figure 4.5  Plasma apelin concentration in venous blood samples from infused (!) and non-infused arm 
(!) during intrabrachial apelin-36 infusion. *P<0.05, ***P<0.001, one-way ANOVA with post-hoc 
Bonferroni tests. 
ANOVA - analysis of variance. 
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(P<0.001) and acetylcholine (P<0.001) increased blood flow in the infused arm  
(Figure 4.6). Co-infusion of the nitric oxide clamp inhibited the response to 
(Pyr1)apelin-13 and acetylcholine but aspirin had no effect in the presence or absence 
of the nitric oxide clamp (Figure 4.6). 
 
4.5    DISCUSSION 
 
We have assessed the direct in vivo effects of the two predominant apelin isoforms in 
man in the human forearm vascular bed. Apelin causes rapid onset, sustained and 
reproducible vasodilatation in peripheral resistance vessels through a nitric oxide-
dependent mechanism.  
 
4.5.1   CHARACTERISATION OF VASODILATOR RESPONSES TO APELIN 
We measured changes in FBF and plasma apelin concentrations during local intra-
arterial infusions of two apelin isoforms: apelin-36, the full-length mature peptide, 
and (Pyr1)apelin-13, a shorter C-terminal fragment. At infusion rates >3 nmol/min, 
we detected a rise in plasma apelin concentrations in the non-infused arm indicating 
spillover of infused apelin into the systemic circulation. This spillover limits 
interpretation of blood flow changes at the higher doses of apelin because of 
potential concomitant effects on myocardial contractility and activation of 
neurohumoral reflexes. However, at apelin doses ≤3 nmol/min, changes in blood 


















































































































































































































































































































































































































































































































































































The onset of vasodilatation in these studies was rapid, occurring within 6 minutes. 
However, the offset was slow, with blood flow in the infused arm consistently 
remaining above baseline during washout periods and persisting for up to 
42 minutes. This prolonged offset of action is unusual but has been described with 
other agonists, such as the vasopressin V2 receptor agonist, desmopressin      
[Affolter et al 2003]. It is consistent with in vitro data showing a prolonged response 
to apelin stimulation in various microphysiometric assays, particularly with apelin-36 
[Masri et al 2006]. The prolonged offset cannot be explained by persistence of the 
peptide in plasma because vasodilatation persisted after plasma apelin concentrations 
had returned to baseline. Indeed, the results of these studies suggest apelin has a 
relatively short plasma half-life of no longer than 8 minutes. 
 
In comparison with other established endothelium-dependent vasodilators, such as 
acetylcholine [Newby et al 1997b], bradykinin [Mills et al 2005] and substance P 
[Newby et al 1997c], the vasodilatation induced by apelin was relatively modest with 
a maximum increase in FBF of 70-80%. With both apelin isoforms, vasodilatation 
appeared to plateau at doses >0.1 nmol/min. One potential explanation for this effect 
is desensitisation of the apelin receptor to ligand activation. In vitro, stimulation with 
either (Pyr1)apelin-13 or apelin-36 causes rapid and dose-dependent internalisation 
of apelin receptors [Reaux et al 2001; Zhou et al 2003] and several apelin-mediated 
signalling cascades are rapidly attenuated by repeated ligand exposure [Choe et al 
2000; Masri et al 2006]. However, in our studies, continuous infusion of 
(Pyr1)apelin-13 elicited sustained, near maximal vasodilatation over a 42-minute 
period. In addition, we did not find a greater vasodilator response with incremental 
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discontinuous infusions than with incremental continuous doses. We therefore 
believe it more likely that the observed plateau in blood flow represents a true ceiling 
of the vasodilator response to apelin rather than desensitisation. 
 
4.5.2   COMPARISON OF APELIN ISOFORMS 
Although shorter apelin fragments are reported to have more potent depressor 
activity than apelin-36 in rodents [Tatmemoto et al 2001] vasodilator responses to 
the two isoforms in this study did not differ at locally active doses. At the maximum 
dose of 30 nmol/min, blood flow in the infused arm increased sharply with apelin-36 
and was greater than that observed with (Pyr1)apelin-13. However this coincided 
with an increase in systemic plasma apelin concentration and blood flow in the non-
infused arm. Given the apparent plateauing of blood flow responses to apelin-36 at 
subsystemic doses and the known inotropic effects of apelin in preclinical 
models [Szokodi et al 2002; Ashley et al 2005], it is tempting to speculate that this 
may have reflected an increase in cardiac contractility. On the other hand, we saw no 
concomitant effect on heart rate or blood pressure and the purpose of the present 
study was to assess the direct vascular effects of apelin. Further appropriately 
designed studies, with higher systemic doses, are needed to address the question of 
whether intravenous apelin infusion can affect systemic haemodynamic and cardiac 
variables.  
 
Whilst both isoforms elicited a rapid onset of vasodilatation, the offset was more 
prolonged following apelin-36 infusion. Indeed the duration of the vasodilatator 
response to apelin-36 remains uncertain as it exceeded the washout time employed in 
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these studies but it is at least 42 minutes. Recent in vitro work exploring the 
interaction of different apelin isoforms with the apelin receptor may provide insights 
into the differing offset of response. Whilst (Pyr1)apelin-13 has a greater binding 
affinity for the apelin receptor, apelin-36 exhibits a much slower dissociation, 
leading to prolonged receptor activation [Masri et al 2006]. Cell lines expressing the 
apelin receptor that are pretreated with apelin-36 show no clear response to 
subsequent apelin stimulation because intracellular responses e.g. inhibition of 
adenylate cyclase, remain maximally activated even after 2 hours [Masri et al 2006]. 
In contrast, intracellular responses to apelin-13 are more transient and show a further 
increase on re-exposure [Masri et al 2006]. Thus it appears that the slow dissociation 
of apelin-36 effectively locks the receptor in an active configuration. Such 
pharmacodynamic differences might potentially underpin distinct physiological roles 
for the different apelin isoforms in vivo. 
 
4.5.3   CONTRIBUTION OF NITRIC OXIDE AND PROSTACYCLIN 
To investigate the mechanism of apelin-mediated vasodilatation, we examined the 
effect of local inhibition of nitric oxide synthesis and systemic inhibition of 
prostaglandin synthesis, alone and in combination, on blood flow responses to 
subsystemic doses of (Pyr1)apelin-13. We found that vasodilatation to       
(Pyr1)apelin-13 was attenuated by two-thirds during the nitric oxide clamp compared 
with saline placebo, indicating that vasodilatation to apelin, is mediated 
predominantly by endothelial nitric oxide generation. As expected, the nitric oxide 
clamp also inhibited acetylcholine-mediated vasodilatation, which is known to be 
mediated in part by nitric oxide [Calver et al 1992]. In contrast to local inhibition of 
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nitric oxide synthase, systemic inhibition of prostanoid generation with oral aspirin 
did not alter vasodilatation to either (Pyr1)apelin-13 or acetylcholine, alone or in 
combination with the nitric oxide clamp. The dose of aspirin used in this study has 
previously been shown to inhibit bradykinin-stimulated endothelial production of 
prostacylin by at least 85% [Heavey et al 1985], suggesting that prostanoids do not 
provide a major contribution to apelin-mediated vasodilatation. The failure of aspirin 
to inhibit acetylcholine-mediated vasodilatation in the human forearm is consistent 
with previous reports [Noon et al 1998; Campia et al 2002]. Our findings in vivo are 
in close agreement with Salcedo et al who recently demonstrated that nitric oxide 
synthase but not cyclooxygenase inhibition attenuated relaxation to apelin in human 
mesenteric arteries in vitro [Salcedo et al 2007].  
 
In the absence of functioning endothelium apelin induces vasoconstriction ex vivo by 
a direct action on vascular smooth muscle cells [Katugampola et al 2001]. However, 
in these studies we observed no evidence of apelin-mediated vasoconstriction, even 
during combined inhibition of nitric oxide and prostacyclin synthesis. 
 
4.5.4   CONCLUSIONS 
Apelin-mediated vasodilatation in the human forearm circulation is reproducible, 
sustained and mediated predominantly by nitric oxide. The vasodilator responses to 











CARDIAC AND SYSTEMIC HAEMODYNAMIC EFFECTS  
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Apelin has major cardiovascular effects in preclinical models. The objectives of this 
study were to establish the effects of acute apelin administration on cardiac and 
systemic haemodynamic variables in man. Systemic haemodynamic variables were 
measured non-invasively by TEB during randomised doubled-blind intravenous 
infusions of apelin-36 or (Pyr1)apelin-13 (30-300 nmol/min) and matched saline 
placebo in eight healthy volunteers. Left ventricular pressures were measured 
invasively by pressure wire in six patients undergoing diagnostic coronary 
angiography following intracoronary bolus injections of apelin-36  (20 and 200 nmol 
in 2 mL) and 0.9% saline (2 x 2 mL) in a double-blind randomised manner, and a 
single-blinded non-randomised bolus of GTN (100 µg in 2 mL). Intracoronary 
apelin-36 increased dP/dtmax, and reduced peak and end-diastolic left ventricular 
pressures (all P<0.05). Systemic infusions of (Pyr1)apelin-13 and apelin-36            
(30-300 nmol/min) increased cardiac index and heart rate and lowered peripheral 
vascular resistance (all P<0.01). Acute apelin administration in man increases cardiac 
contractility and cardiac output whilst lowering peripheral vascular resistance. This 
profile of cardiovascular actions suggests therapeutic potential for apelin receptor 









The apelin receptor (previously known as ‘APJ’) is a novel G protein-coupled 
receptor, originally discovered in 1993 [O’Dowd et al 1993] and subsequently paired 
with its endogenous ligand, apelin in 1998 [Tatemoto et al 1998]. Apelin receptors 
are present on endothelial cells, vascular smooth muscle cells and cardiomyocytes. 
[Kleinz et al 2005] and, in preclinical models, apelin signalling exerts major effects 
on both vascular tone and cardiac contractility. In isolated rat hearts, apelin is the 
most potent endogenous inotrope yet described [Szokodi et al 2002] and, in ex vivo 
myography studies, it causes vasorelaxation in human mesenteric artery that is 
attenuated by inhibition of nitric oxide but not prostacyclin [Salcedo et al 2007]. In 
rodents, apelin increases cardiac contractility in vivo [Ashley et al 2005; Atluri et al 
2007] and causes a rapid fall in both arterial blood pressure and systemic venous tone 
[Tatemoto et al 2001; Cheng et al 2003; Lee et al 2005] with corresponding 
reductions in left ventricular afterload and preload [Ashley et al 2005]. If replicated 
in clinical studies such a profile of cardiovascular actions might suggest a potential 
role for apelin receptor agonism in the treatment of heart failure.  
 
We recently provided the first evidence that apelin has vasoactive actions in vivo in 
man [Japp et al 2008]. We demonstrated that local apelin administration causes 
vasodilatation in the coronary circulation and peripheral resistance vessels with no 
apparent effect on peripheral venous tone. In the current series of studies, we sought 
to further characterise the in vivo cardiovascular profile of apelin in man by 





All studies were performed with the written informed consent of volunteers, the 
approval of the local Research Ethics Committee and in accordance with the 
Declaration of Helsinki. 
 
5.3.1   SUBJECTS 
Eight healthy volunteers aged between 21 and 27 years and six patients attending for 
elective outpatient diagnostic coronary angiography participated in these studies. 
Healthy volunteers were not taking any regular medication and had no history of any 
clinically significant medical condition or symptoms of recent infective or 
inflammatory illness. Patients attending for diagnostic angiography were excluded if 
they were found to have left main stem stenosis or severe coronary artery stenosis, 
previous coronary intervention, and clinical or echocardiographic evidence of cardiac 
failure. Patients withheld their usual medications on the day of the study until 
completion of the study protocol and all participants abstained from alcohol for 
24 hours and from food and caffeine-containing drinks for at least 4 hours before 
each study.  
 
5.3.2   DRUGS 
The effects of apelin receptor agonism were assessed using synthetic 
pharmaceutical grade apelin-36 and (Pyr1)apelin-13. GTN was administered as a 
control vasodilator.  
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5.3.3   MEASUREMENTS 
All studies were carried out in a quiet, temperature-controlled room (23-25°C) with 
subjects in the supine position.  
 
Myocardial Contractility Studies 
Following diagnostic coronary angiography, a coronary guide catheter was engaged 
in the ostium of the left coronary artery. Coronary blood flow was measured as 
described in Chapter 3. A further catheter was inserted into the left ventricle and a 
0.014-inch pressure wire placed in the left ventricular cavity to allow continuous 
measurement of left ventricular pressure [Duckett et al 2011; Ginks et al 2011]. The 
output from the pressure wire was connected to a RadiAnalyzer® and transferred to 
a laptop computer with PhysioMon® software to give curves showing real-time 
blood pressure and left ventricular dP/dtmax. Ten-second samples of pressure 
recordings within the left ventricle were taken before and at 60 seconds after each 
drug bolus and used to calculate dP/dtmax, LV max and LVEDP.  
 
Systemic Haemodynamic Studies 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the 
antecubital fossae of both arms to allow drug infusion and sampling of venous blood. 
Blood pressure and heart rate were recorded with a semi-automated non-invasive 
oscillometric sphygmomanometer; mean arterial pressure was defined as the sum of 
the diastolic blood pressure and a third of the pulse pressure. Cardiac output was 
measured non-invasively using a TEB monitor [Northridge et al 1990] and corrected 
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for body surface area to give cardiac index. At each time point, cardiac output was 
taken as the mean of three recordings, each recording representing the average of 
16 consecutive heartbeats. Peripheral vascular resistance index was calculated as 
mean arterial pressure divided by cardiac index and expressed in dyne.s/cm5/m2. 
Continuous electrocardiographic monitoring was performed during all studies. 
 
Apelin Assay 
Blood samples (10 mL) were drawn into tubes containing EDTA and kept on ice 
before centrifugation at 2000 g for 30 minutes at 4°C. Platelet-free plasma was 
decanted and stored at -80°C before assay. Plasma apelin-36 concentration was 
measured using a commercially available apelin-12 micro-plate ELISA Kit. 
 
5.3.4   PROTOCOL DESIGN  
Protocol 1: Myocardial contractility studies 
As previously described in Chapter 3, six subjects received intracoronary boluses via 
the coronary guide catheter of apelin-36 (20 and 200 nmol in 2 mL) and 0.9% saline 
(2 x 2 mL) in a double-blind randomised manner, followed by a single-blinded non-
randomised bolus of GTN (100 µg in 2 mL). All drug boluses were followed by a    
2 mL 0.9% saline flush and 5-minute washout intervals were allowed between drugs. 
Left ventricular dP/dtmax, LV max and LVEDP, as well as coronary blood flow (see 





Protocol 2: Systemic haemodynamic studies  
Eight subjects attended on two occasions at least one week apart. In a double-blind 
randomised manner, three incremental intravenous doses of either apelin-36 or 
(Pyr1)apelin-13 (30, 100, 300 nmol/min) were given for 5 minutes at each dose and 
compared with three matched saline placebo infusions. Doses of apelin were 
determined from our previous study [Japp et al 2008] where 30 nmol/min caused a 
rise in systemic plasma apelin concentrations. Apelin and saline infusions were 
separated by a 30-minute saline infusion. Haemodynamic recordings were made at 
10-minute intervals prior to commencement of drug infusion and at 5-minute 
intervals thereafter. Venous blood samples were obtained at baseline, at peak drug 
infusion and at 5 and 30-minute post drug infusion for measurement of plasma apelin 
concentration. 
 
5.3.5  DATA AND STATISTICAL ANALYSES 
Cardiac and systemic haemodynamic variables were analysed in a blinded fashion. 
Variables are reported as mean ± SEM and analysed using repeated measures 
ANOVA with post-hoc Bonferroni corrections and two-tailed Student’s t-test as 
appropriate. Statistical significance was taken at the 5% level.  
 
5.4     RESULTS 
 
All studies were well tolerated with no serious adverse events or ECG changes 
during apelin administration.  
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5.4.1   MYOCARDIAL CONTRACTILITY 
Patients were aged 60 ± 4 years and five were male. All patients had near normal 
coronary arteries with no haemodynamically significant flow limiting stenoses     
(<25% luminal stenosis). Owing to a technical computer failure during one of the 
studies, incomplete haemodynamic data were obtained for one subject. Consequently 
the analyses for left ventricular pressure are based on n=5. 
 
As described in Chapter 3, both the higher dose of apelin and GTN caused an 
increase in coronary blood flow. There were no significant changes in 
haemodynamic variables following injection of 20 nmol apelin-36 (data not shown). 
In comparison with placebo, both 200 nmol apelin-36 and GTN caused an increase in 
dP/dtmax and a slight reduction in LV max and LVEDP (Figure 5.1). In comparison 
with placebo, GTN caused a fall in mean arterial pressure (94 ± 8 versus 
80 ± 9 mmHg, P<0.01) and rise in heart rate (67 ± 5 versus 69 ± 5 bpm, P<0.001) but 
apelin had no effect on blood pressure (94 ± 8 versus 94 ± 7 mmHg, P=0.9) or heart 
rate (67 ± 5 versus 68 ± 5 bpm, P=0.3).  
 
5.4.2   SYSTEMIC HAEMODYNAMICS 
Saline placebo infusion had no effect on any of the haemodynamic variables            
(P>0.05, one-way ANOVA). Compared with saline placebo, both (Pyr1)apelin-13 
and apelin-36 increased heart rate and cardiac output whilst reducing peripheral 
vascular resistance (Figures 5.2 and 5.3). There appeared to be no clear dose-
response relationship at the doses employed in the present study and, consistent with 





















































Figure 5.1  Left ventricular pressure variables following bolus injection of apelin-36 (200 nmol), 
GTN (100 µg) and 0.9% saline. *P<0.05, paired student’s t-test versus 0.9% saline. 
GTN - glyceryl trinitrate; LV dP/dtmax - left ventricular maximum rate of rise in pressure; LVEDP - 
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Figure 5.2    Heart rate and blood pressure during infusion of apelin (!) or matched saline placebo 
(") in healthy subjects. Two-way ANOVA (apelin versus placebo). 
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Figure 5.3   Cardiac index and peripheral vascular resistance index during infusion of apelin (!) or 
matched saline placebo (") in healthy subjects. Two-way ANOVA (apelin versus placebo). 
ANOVA - analysis of variance; PVRI - peripheral vascular resistance index. 
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than (Pyr1)apelin-13 (Figure 5.4). The small rise in heart rate was seen early and was 
not sustained (Figure 5.4). With both isoforms there was a trend towards a reduction 
in blood pressure that did not reach statistical significance (Figure 5.3). Plasma 
concentration of apelin-36 increased from 0.24 ± 0.07 pg/mL at baseline to 
115.86 ± 16.97 pg/mL during maximal infusion of apelin-36 (P<0.0001); and by 
5 minutes post infusion had fallen to 39.95 ± 7.82 pg/mL (P=0.002 versus peak 
infusion) suggesting a plasma half-life of less than 5 minutes. By 30 minutes 
post infusion, plasma apelin concentrations had returned to near baseline 
(1.56 ± 0.55) and did not differ from baseline values (P>0.05). 
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Figure 5.4  Systemic haemodynamic variables during graded infusions of (Pyr1)apelin-13 (!) or 
apelin-36 (") followed by 0.9% saline washout. *P<0.05, **P<0.01, ***P<0.001, one-way ANOVA 
with post-hoc Bonferroni tests (apelin versus baseline). 
ANOVA - analysis of variance; PVRI - peripheral vascular resistance index. 
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5.5    DISCUSSION 
 
For the first time, we have demonstrated that acute apelin infusion in man reduces 
peripheral arterial resistance, alters cardiac loading conditions and increases cardiac 
contractility and output.  
 
In keeping with its actions in preclinical models, acute apelin infusion in man 
decreases peripheral vascular resistance whilst increasing heart rate and cardiac 
output. We have previously shown that local apelin infusion causes           
nitric oxide-mediated vasodilatation in the human forearm circulation [Japp et al 
2008]. In the present study we extend this work by confirming that the direct 
vascular actions of apelin modulate systemic haemodynamics. The increase in heart 
rate in our study occurred early and was not sustained. In rodents a similar rise in 
heart rate following apelin administration is abolished by ganglionic blockade 
[Cheng et al 2003]. We therefore believe it is more likely to represent a reflex 
sympathetic response to peripheral vasodilatation than a direct chronotropic effect. 
Similarly, the observed increase in cardiac output is likely to be explained at least in 
part through peripheral arterial vasodilation via a reduction in afterload and 
activation of compensatory neurohormonal reflexes. In rodents apelin-mediated 
vasodilatation is associated with a marked depressor response [Tatemoto et al 2001; 
Lee et al 2005] whereas in our study no significant blood pressure changes were 
observed. Of note the blood pressure lowering effects of apelin in preclinical models 
peak within 60 seconds and decline rapidly thereafter [Lee et al 2005]. However we 
measured blood pressure at 5-minute intervals during apelin infusion. Additionally, 
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our study may have been underpowered to detect a small reduction in blood pressure. 
Consequently, this apparent discrepancy may reflect an inability of our protocol to 
detect an early transient rise in blood pressure rather than a true interspecies 
difference. 
 
We assessed the haemodynamic effects of two apelin isoforms: apelin-36, the full-
length mature peptide, and (Pyr1)apelin-13, a shorter C-terminal fragment. In 
preclinical studies the shorter isoform is reported to exhibit greater binding affinity 
[Hosoya et al 2000; Masri et al 2006] and more potent cardiovascular effects 
[Tatemoto et al 2001]. Here the magnitude of haemodynamic effects elicited by the 
two isoforms was equivalent, though, consistent with in vitro data and our findings in 
the forearm circulation, the responses to apelin-36 exhibited a slower offset. The 
changes in systemic haemodynamic variables did not demonstrate a clear            
dose-response relationship and appeared to demonstrate a flat dose-response. This 
was also seen in our previous studies in the peripheral forearm circulation [Japp et al 
2008] and may reflect our selection of doses or an ‘all-or-nothing’ response.  
 
The observed rise in cardiac output during systemic apelin administration may, at 
least in part, have been a reflex response to peripheral vasodilatation. However 
preclinical data suggest that apelin also exerts direct positive inotropic effects. 
[Szokodi et al 2002]. In order to assess the in vivo cardiac effects of apelin in man 
we measured left ventricular pressures during intracoronary apelin administration. 
Consistent with direct effects on myocardial contractility, apelin caused an increase 
in dP/dtmax. However the increase occurred only with the higher dose of apelin and 
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was associated with a concomitant reduction in both LV max and LVEDP indicating 
likely systemic vascular effects. Whilst we did not measure peripheral plasma apelin 
concentrations during these studies, the administered dose exceeded that required to 
generate systemic effects and a rise in plasma apelin levels in our intravenous 
studies. Of note, a very similar haemodynamic profile of effects occurred following 
GTN injection. We therefore believe it is likely that there was overspill of both 
apelin and GTN in to the peripheral circulation leading to alterations in peripheral 
vascular tone. This interpretation is supported by the apparent absence of any direct 
cardiac effects following injection of the lower dose of apelin and would be in 
keeping with the clear evidence of peripheral arterial vasodilatation in our forearm 
and systemic infusion studies. Consequently, our data do not provide definitive 
evidence of a direct effect of apelin on myocardial contractility in vivo in man. 
However, in contrast to GTN, which caused a marked fall in systemic blood pressure 
and corresponding rise in heart rate, the higher dose of apelin had no effect on blood 
pressure or heart rate, raising the possibility of an additional direct inotropic effect.  
 
Although the presumed systemic spillover during intracoronary administration 
confounds assessment of the direct cardiac effects of apelin, the resultant changes in 
loading conditions provide the first evidence that the direct vascular effects of apelin 
couple to the left ventricle. Furthermore, the observed reduction in LVEDP suggests 
for the first time that apelin causes venodilatation in man. Whilst we have previously 
reported that apelin has no apparent effect on venous tone in superficial hand veins 
[Japp et al 2008] these veins are not representative of other venous beds and are of 
less haemodynamic importance than deep capacitance veins [Schmitt et al 2002]. 
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The finding that apelin reduces interspecies LVEDP in man is consistent with 
evidence of a powerful venodilator effect in rodents [Cheng et al 2003]. 
 
Reductions in myocardial expression of apelin and the apelin receptor have been 
demonstrated in experimental rodent models of heart failure [Iwanaga et al 2006; Jia 
et al 2006]. Failing human hearts exhibit similarly altered expression patterns and 
patients [Foldes et al 2003], with severe chronic heart failure have reduced plasma 
apelin concentrations [Chong et al 2006]. Given the cardiovascular actions of apelin 
described above, this apparent down regulation of the apelin pathway might 
conceivably contribute to the pathophysiology of heart failure and suggests 
therapeutic potential for apelin receptor agonism. To date there have been no reports 
of the effects of apelin in patients with heart failure. Encouragingly however, the 
cardiovascular effects of exogenous apelin are maintained or even increased in 
rodents with heart failure suggesting, scope to augment endogenous apelin 
signalling.  
 
5.5.1   STUDY LIMITATIONS 
We acknowledge that this study has only assessed the acute effects of apelin 
administration. Our data on the direct cardiac effects of apelin are not definitive and 
we believe that further work is needed to assess the load-independent effects of 
apelin on myocardial contractility. To determine whether apelin causes                 
load-independent increases in myocardial contractility is challenging in a clinical 
study and would require the use of a conductance catheter with manipulation of 
cardiac filling pressures.  
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5.5.2   CONCLUSIONS 
Consistent with its effects in preclinical models, we have shown that acute apelin 
administration causes peripheral vasodilatation, augments cardiac contractility and 
output and reduces left ventricular preload and afterload. If replicated in suitable 
patient populations, this profile of cardiovascular actions would suggest a potential 








CHAPTER  6 
 
CARDIOVASCULAR RESPONSES TO APELIN IN  





















Japp AG, Cruden NL, Barnes G et al. 
Acute cardiovascular effects of apelin in humans: 





The apelin system mediates important cardiovascular effects in preclinical and 
clinical models. The study objectives were to establish the direct vascular and 
systemic haemodynamic effects of acute apelin agonism in patients with stable 
chronic heart failure and matched healthy control subjects. Forearm blood flow was 
measured by venous occlusion plethysmography during intrabrachial infusions of 
(Pyr1)apelin-13 (0.3, 1, 3 nmol/min), acetylcholine (5, 10, 20 µg/min) and SNP (1, 2, 
4 µg/min) in 12 patients and 12 controls. Cardiac output, peripheral vascular 
resistance, blood pressure and heart rate were assessed by thoracic bioimpedance and 
sphygmomanometry during intravenous infusions of (Pyr1)apelin-13 (30, 100, 
300 nmol/min) and matched saline placebo in 8 patients and 8 controls. (Pyr1)apelin-
13, acetylcholine and SNP caused forearm vasodilatation in patients and controls (all 
P<0.0001). Vasodilatation to acetylcholine (P=0.01) but not apelin (P=0.3) or SNP 
(P=0.9) was attenuated in patients with heart failure. Systemic infusions of 
(Pyr1)apelin-13 (30-300 nmol/min) increased cardiac index and lowered mean 
arterial pressure and peripheral vascular resistance in patients and controls (all 
P<0.01) but increased heart rate only in controls (P<0.01). The direct vascular and 
systemic haemodynamic effects of apelin are preserved in patients with stable 
chronic heart failure. Apelin receptor agonism represents a novel potential 







Apelin and the apelin receptor (previously known as ‘APJ’) constitute a recently 
discovered peptidic system with an emerging role in cardiovascular regulation 
[O’Dowd et al 1993; Tatemoto et al 1998; Pitkin et al 2010a] and potential 
therapeutic application in heart failure.  
 
Mice with deletion of the apelin gene develop premature heart failure unless plasma 
apelin concentrations are restored [Kuba et al 2007]. In healthy rodents, exogenous 
apelin potently enhances myocardial contractility without inducing left ventricular 
hypertrophy [Ashley et al 2005] and achieves this whilst simultaneously reducing 
ventricular preload and afterload. These effects are maintained in preclinical models 
of heart failure: in vitro, apelin increases contractility in the failing myocardium to 
the same [Farkasfalvi et al 2007] or greater [Dai et al 2006] extent as in the normal 
myocardium and, in vivo, acute apelin infusion restores ejection fraction, increases 
cardiac output and reduces LVEDP in rats with chronic heart failure [Berry et al 
2004; Jai et al 2006]. 
 
We recently provided the first evidence that apelin has cardiovascular actions in vivo 
in man [Japp et al 2008]. In healthy volunteers, apelin causes nitric oxide-mediated 
peripheral vasodilatation and increases cardiac output whilst, in patients undergoing 
elective coronary angiography, it reduces left ventricular preload and increases 
cardiac contractility.  
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Paralleling findings in rodent models, failing human hearts exhibit altered expression 
patterns of apelin and its receptor [Foldes et al 2003] whilst patients with severe 
chronic heart failure have reduced plasma apelin levels [Chong et al 2006]. The 
impact of these changes on apelin-mediated biological effects has not previously 
been investigated. Therefore, as a first step to exploring the therapeutic potential of 
apelin receptor agonism in heart failure, we sought to determine the local vascular, 
systemic haemodynamic and neurohormonal effects of acute apelin administration in 




All studies were performed with the written informed consent of volunteers, the 
approval of the local Research Ethics Committee and in accordance with the 
Declaration of Helsinki. 
 
6.3.1   SUBJECTS 
Patients with heart failure were eligible for inclusion if they had stable NYHA class 
II-IV symptoms, were on maximally tolerated doses of heart failure medication for at 
least 3 months, and had objective evidence of left ventricular impairment (left 
ventricular end-diastolic diameter >5.5 cm and left ventricular ejection fraction 
<40% or shortening fraction <20%) [Cruden et al 2004]. Patients were excluded if 
they had haemodynamically significant valvular heart disease, renal or hepatic 
failure, or had previous malignant ventricular arrhythmias. Control volunteers had no 
history of any clinically significant medical condition or symptoms of recent illness 
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and avoided vasoactive and non-steroidal anti-inflammatory drugs for 7 days prior to 
studies. Patients withheld their usual medications on the day of the study until 
completion of the study protocol and all participants abstained from alcohol for 
24 hours and from food and caffeine-containing drinks for at least 4 hours before 
each study.  
 
6.3.2   DRUGS 
The effects of apelin receptor agonism were assessed using synthetic 
pharmaceutical grade (Pyr1)apelin-13. Acetylcholine and SNP were administered as 
endothelium-dependent and independent control vasodilators respectively.  
 
6.3.3   MEASUREMENTS 
All studies were carried out in a quiet, temperature-controlled room (23-25°C) with 
subjects in the supine position.  
 
Peripheral Arterial Studies 
Subjects underwent brachial artery cannulation with a 27-standard wire gauge steel 
needle under controlled conditions and the rate of infusion was kept constant at          
1 mL/min. Blood flow was measured in the infused and non-infused forearms by 
bilateral forearm venous occlusion plethysmography using mercury-in-silastic strain 
gauges as described previously [Newby et al 1997a; Newby et al 1999]. 
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Systemic Haemodynamic Studies 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the 
antecubital fossae of both arms to allow drug infusion and sampling of venous blood. 
Blood pressure and heart rate were recorded with a semi-automated non-invasive 
oscillometric sphygmomanometer; mean arterial pressure was defined as the sum of 
the diastolic blood pressure and a third of the pulse pressure. Cardiac output was 
measured non-invasively using a TEB monitor [Northridge et al 1990] following 
manufacturer’s guidelines and corrected for body surface area to give cardiac index. 
At each time point, cardiac output was taken as the mean of three recordings, each 
recording representing the average of 16 consecutive heartbeats. Peripheral vascular 
resistance index was calculated as mean arterial pressure divided by cardiac index 
and expressed in dyne.s/cm5/m2. Continuous electrocardiographic monitoring was 
performed during all studies. 
 
Assays 
Blood samples (10 mL) were drawn into tubes containing either EDTA or lithium 
heparin, and kept on ice before centrifugation at 2000 g for 30 minutes at 4°C. 
Platelet-free plasma was decanted and stored at -80°C before assay. Plasma renin 
activity was measured under standard conditions through the generation of 
angiotensin I as determined by radioimmunoassay [Haber et al 1969]. Plasma BNP 





6.3.4   PROTOCOL DESIGN (Figure 6.1) 
Protocol 1: Peripheral arterial studies 
Twelve patients with heart failure and 12 age- and sex-matched healthy controls 
attended on a single occasion and had blood drawn for baseline measurement of BNP 
and plasma renin activity. In a double-blinded randomised manner, all subjects then 
received intrabrachial infusions of (Pyr1)apelin-13 (0.3, 1, 3 nmol/min) [Japp et al 
2008], acetylcholine (5, 10, 20 µg/min) [Japp et al 2008] and SNP (1, 2, 4 µg/min) 
[Taddei et al 1998] for 6 minutes at each dose with drugs separated by a 20-minute 
saline infusion. Blood flow was measured at 6-minute intervals throughout the study 
in the infused and non-infused forearms by venous occlusion plethysmography. 
 
Protocol 2: Systemic haemodynamic studies 
Eight patients with heart failure and eight healthy matched controls attended on a 
single occasion. In a double-blind randomised manner, intravenous (Pyr1)apelin-13 
(30, 100, 300 nmol/min) and matched saline placebo were infused for 5 minutes at 
each dose. Apelin and saline infusions were separated by a 30-minute saline infusion. 
Haemodynamic recordings were made at 10-minute intervals prior to 
commencement of drug infusion and at 5-minute intervals thereafter. Venous blood 
samples were obtained at baseline and at 5, 15 and 30 minutes post drug infusion for 
measurement of BNP, AVP and plasma renin activity. 
 
 
   


























































   


































































































































































































































































6.3.5   DATA AND STATISTICAL ANALYSES 
Forearm and systemic haemodynamic variable were analysed as described 
previously [Newby et al 1997a, Leslie et al 2005]. Plasma renin activity and BNP 
concentrations were not normally distributed and were therefore log transformed 
prior to statistical analysis. In order to minimise the effects of intergroup variability 
in baseline haemodynamic and blood flow variables, responses to drug infusion are 
expressed as percentage change from baseline. Variables are reported as 
mean ± SEM and, where appropriate analysed using repeated measures ANOVA 
with post-hoc Bonferroni corrections and two-tailed Student’s t-test as appropriate. 
Statistical significance was taken at the 5% level.  
 
6.4    RESULTS 
 
All studies were well tolerated with no serious adverse events or ECG changes 
during apelin administration. Patients with heart failure were predominantly male 
and middle-aged with the aetiology attributable to ischaemic heart disease or dilated 
cardiomyopathy (Table 6.1). They were well treated with optimal or maximally 
tolerated heart failure therapy and had mild to moderate symptoms with a low 
ejection fraction and elevated BNP concentrations and plasma renin activity     
(Table 6.1).  
 
Peripheral Blood Flow 
There was an apparent trend towards lower basal FBF in patients with heart failure, 
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There was no significant change in heart rate, blood pressure or non-infused FBF in 
either patients or controls. In the infused arm, (Pyr1)apelin-13, acetylcholine and 
SNP caused vasodilatation (P<0.001) in both healthy volunteers and patients with 
heart failure (Figure 6.2). Whilst vasodilatation to (Pyr1)apelin-13 and SNP was 
similar between the groups, vasodilatation to acetylcholine was reduced in patients 
with heart failure.  
 
Systemic Haemodynamic Studies 
Compared with saline placebo, intravenous administration of (Pyr1)apelin-13 caused 
an increase in cardiac output, and reductions in blood pressure and peripheral 
vascular resistance in both patients and controls as well as an increase in heart rate in 
controls (P<0.01 for all; Figure 6.3 and Table 6.2). There were no differences in the 
responses to apelin between patients with heart failure and controls, with the 
exception of heart rate, in which a greater response to apelin was observed in 
controls (P<0.05; Figure 6.4).  
 
At baseline, plasma BNP concentration and plasma renin activity were both higher in 
patients compared with controls (both P<0.01) whilst plasma AVP concentration did 
not differ significantly between the two groups (P=0.24; Table 6.1). There was no 
change in any of these variables in either group at 5, 15 and 30 minutes after apelin 
infusion (Figure 6.5). 
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Figure 6.2  Infused forearm blood flow in patients with chronic heart failure (!) and matched 
controls (") during intrabrachial infusion of (Pyr1)apelin-13, acetylcholine and SNP: for all dose-
responses P<0.001 (ANOVA); for patients versus controls (Pyr1)apelin-13 (P=0.3), acetylcholine 
(P<0.05) and SNP (P=0.9).   





Figure 6.3  Percentage change from baseline in mean arterial pressure, heart rate, cardiac index and 
peripheral vascular resistance index during infusion of (Pyr1)apelin-13 (!) and saline placebo (") in 
patients with chronic heart failure (left hand panel) and matched controls (right hand panel): for all 
dose-responses, P<0.01 compared with saline placebo (two-way ANOVA), except change in heart 
rate in patients (P=ns)  
ANOVA - analysis of variance; ns - not significant; CHF - chronic heart failure; PVRI - peripheral 
vascular resistance index. 
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Figure 6.4  Percentage change from baseline in mean arterial pressure, heart rate, cardiac index and 
peripheral vascular resistance index during infusion of (Pyr1)apelin-13 in patients with chronic heart 
failure (!) and matched controls ("). Two-way ANOVA (patients versus controls) heart rate, P<0.05; 
mean arterial pressure, cardiac index and peripheral vascular resistance index, P=ns. 
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Figure 6.5  Plasma BNP and AVP concentrations and plasma renin activity in venous blood samples 
from heart failure patients (#) and matched controls (#) before and after infusion of (Pyr1)apelin-13. 
**P<0.01, ***P<0.001, two-way ANOVA (patients versus controls) with post-hoc Bonferroni tests. 




6.5     DISCUSSION 
 
In both preclinical and clinical models, the apelin system mediates important 
cardiovascular effects, reducing peripheral vascular resistance through      
nitric oxide-mediated arterial vasodilatation whilst increasing cardiac contractility 
and output. We here report that the direct vascular and systemic haemodynamic 
effects of apelin are preserved in patients with stable chronic heart failure. We 
conclude that apelin receptor agonism has potential therapeutic benefits in patients 
with heart failure maintained on optimal contemporary medical therapy. 
 
We have previously shown, in keeping with data from animal and ex vivo models, 
that apelin causes vasodilatation in vivo in the human forearm circulation through 
predominantly nitric oxide-dependent mechanisms [Salcedo et al 2007]. In these 
studies we extend this work to demonstrate that apelin-induced vasodilatation is 
preserved in patients with heart failure. Whilst the study may have been 
underpowered to detect small intergroup differences, we saw no evidence of a major 
attenuation of vasodilatation to apelin in patients with heart failure. This is perhaps 
surprising as the same patients demonstrated reduced vasodilatation to acetylcholine 
that, like apelin, relies predominantly on endothelium-dependent pathways. One 
possible explanation is that alterations in endogenous plasma apelin concentrations 
[Chong et al 2006] or apelin receptor expression [Foldes et al 2003] in the setting of 
heart failure may augment responses to exogenous apelin and thereby offset any 
diminution of endothelial function. On the other hand, it is controversial whether 
patients with stable treated heart failure have evidence of major endothelial 
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dysfunction [Negrao et al 2000] especially when maintained on optimal medical 
therapy. Given the rapidity of its metabolism, the reduced vasodilatation to 
acetylcholine in patients with heart failure may be due to lower basal blood flow 
rather than endothelial dysfunction per se [Chowienczyk et al 1994]. 
 
In both patients with chronic heart failure and healthy adults, systemic apelin 
administration causes a reduction in peripheral vascular resistance accompanied by 
an increase in cardiac output. In a previous study in young healthy subjects         
(aged 21-27 years), heart rate increased slightly while blood pressure was maintained 
[Japp et al 2008]. In an older cohort of healthy subjects in this study we observed a 
similar increase in heart rate with a transient drop in blood pressure. Finally, in heart 
failure patients, apelin elicited no change in heart rate but a sustained reduction in 
blood pressure. We believe the most likely explanation for these differing patterns of 
heart rate and blood pressure response to apelin relates to blunting of reflex 
sympathetic activation and other neurohormonal responses to peripheral 
vasodilatation, caused by ageing, drug therapy (particularly beta-blockade) and, 
possibly, heart failure per se.  
 
Consistent with our previous study in healthy volunteers, the changes in 
haemodynamic variables in both patients and controls, failed to exhibit a clear dose-
response relationship. This was also seen in our previous studies in the forearm 
circulation where vasodilator responses to apelin plateaued early despite repeated 
dose escalation [Japp et al 2008]. In the same model, continuous infusion of 
(Pyr1)apelin-13 for 42 minutes elicited sustained, near-maximal vasodilatation 
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suggesting that this plateauing of effect was due to a ceiling of apelin-mediated 
vasodilatation rather than rapid apelin receptor desensitisation. Accordingly, the flat 
dose-response to apelin in these studies is unlikely to represent tachyphylaxis but 
may reflect our selection of doses or an ‘all-or-nothing’ response.  
 
The mechanisms by which apelin increases cardiac output in man have yet to be fully 
established. These and our previous studies strongly suggest a contribution from 
peripheral arterial vasodilatation. However, the possibility of an additional direct 
effect on myocardial contractility is suggested by the potent inotropic effects of 
apelin in vitro [Szokodi et al 2002] and the load-independent increases in cardiac 
contractility observed in vivo in rodent models [Ashely et al 2005]. Whilst we have 
previously demonstrated an increase in cardiac contractility following intracoronary 
apelin administration in man, we were unable to infer a direct inotropic effect due to 
concomitant changes in loading conditions suggesting overspill of intracoronary 
apelin in to the peripheral circulation and consequent systemic vascular effects. In 
support of an additional direct cardiac action, recent in vitro studies have 
demonstrated, for the first time, that apelin has inotropic effects in human cardiac 
tissue. Nonetheless, a direct effect of apelin on myocardial contractility in vivo in 
man has yet to be demonstrated conclusively. 
 
Although apelin exerts similar effects to BNP on coronary blood flow, systemic 
haemodynamics and fluid balance, the lack of rise in plasma BNP following apelin 
administration confirms that its acute cardiovascular effects are not mediated via 
BNP release. Whether chronic apelin administration alters plasma BNP levels in 
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patients with chronic heart failure will be an important research question for future 
studies exploring the potential therapeutic effects of apelin receptor agonism.  
 
In preclinical models, apelin opposes the actions of AVP on fluid homeostasis and, 
when administered centrally, inhibits AVP release [De Mota et al 2004]. Mounting 
evidence also suggests a direct counter-regulatory role for apelin in relation to the 
renin-angiotensin system [Ashley et al 2006; Chun et al 2008]. In these studies we 
observed no changes in plasma renin activity or AVP concentration for up to 
30 minutes following peak apelin infusion suggesting that apelin does not inhibit 
acute secretion of renin or AVP under normal physiological conditions or in 
compensated heart failure in man. However further dedicated studies are required to 
explore potential functional interactions between these systems in vivo over a 
broader time frame and under varying physiological conditions. 
 
In considering apelin as a potential therapeutic target for patients with heart failure, 
the haemodynamic profile of action described above is broadly favourable. Some 
established inotropic therapies have been associated with adverse outcomes in this 
patient group and, in particular, agents that act by increasing intracellular calcium 
concentrations tend to increase myocardial oxygen consumption, exert pro-
arrhythmic effects and promote left ventricular hypertrophy. However, in preclinical 
models, apelin appears to exert its inotropic effects at least in part through increasing 
myofilament sensitivity to calcium and does not induce left ventricular hypertrophy, 
even during chronic administration. In addition, its ability to reduce cardiac loading 
conditions may serve to limit cardiac work and myocardial oxygen consumption. 
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There are now several reports of reduced plasma apelin concentrations in patients 
with heart failure [Japp and Newby 2008] suggesting scope to augment apelin 
activity. By demonstrating preserved local and systemic cardiovascular responses to 
exogenous apelin in patients with heart failure, we here confirm that the signalling 
capacity of apelin receptors is not exhausted by endogenous apelin in this patient 
cohort - an essential prerequisite for therapeutic strategies employing apelin receptor 
agonism.  
 
The clinical relevance of our findings is enhanced by the inclusion of patients 
maintained on existing evidence-based pharmacological therapies. This is 
particularly important given the recent emergence of direct interactions between the 
renin-angiotensin and apelin systems including direct antagonism of angiotensin II 
by apelin [Iwanaga et al 2006; Chun et al 2008]. As all but one of our patients with 
heart failure were receiving treatment with ACE inhibitors or angiotensin receptor 
blockers, our findings imply a role for apelin in cardiovascular regulation 
independent of angiotensin II signalling pathways and suggest potential for 
pharmacological synergism through combined apelin receptor agonism and renin-
angiotensin system inhibition. 
 
We acknowledge that this study has only assessed the acute effects of apelin 
administration. We cannot reliably infer the consequences of chronic apelin 
administration in patients with chronic heart failure. However, our study would 
suggest that apelin infusion might be of benefit in patients with acute decompensated 
heart failure where these haemodynamic effects of vasodilatation, increased cardiac 
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output, reduced preload, and potential inotropy would be beneficial.  
 
6.5.1   CONCLUSION 
To date, both preclinical and limited clinical studies suggest that the apelin system 
may have an important role in the pathogenesis of heart failure. Although the apelin 
pathway appears to be down regulated in cardiac failure, we have shown that the 
favourable haemodynamic actions of apelin persist and are additive to the effects of 
renin-angiotensin system inhibition. Apelin receptor agonism may therefore provide 























Heart failure constitutes a major and growing health burden in developed nations. 
Despite considerable treatment advances over the past two decades, it has a 
prognosis worse than that of many cancers and results in severe morbidity with 
impaired quality of life and recurrent hospitalisation [Young et al 2004; Cleland et al 
2005; Mosterd and Hoes 2007]. The development of novel treatments for patients 
with heart failure therefore remains a major priority. G protein-coupled receptors 
play an essential role in the physiological control of the cardiovascular system and 
represent the greatest target for existing pharmacological treatments [Foord et al 
2005; Maguire and Davenport 2005]. Many of the recent pharmacological advances 
in the treatment of heart failure, including AT1 and beta-adrenergic receptor 
blockers, have arisen through the specific targeting of G protein-coupled receptor 
systems, and have provided additive incremental morbidity and mortality benefit 
[CIBIS-II Investigators 1999; MERIT-HF Study Group 1999; Packer et al 2001; 
McMurray et al 2003].  
 
In 1993 a novel G protein-coupled receptor, originally called ‘APJ’ and since 
renamed the ‘apelin receptor’ was identified through reverse homology cloning 
[O’Dowd et al 1993] and subsequently paired with its endogenous ligand, apelin 
[Tatemoto et al 1998]. In preclinical models, exogenous apelin mediates nitric oxide-
dependent vasodilatation, reduces ventricular preload and afterload, and potently 
increases myocardial contractility without inducing left ventricular hypertrophy 
[Tatemoto et al 2001, Ashley et al 2005]. In rodents the endogenous apelin system is 
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up regulated by hypoxia [Ronkainen et al 2007; Sheikh et al 2008] and pressure 
overload [Iwanaga et al 2006] and apelin signalling appears to be critical in 
maintaining cardiac function during cardiovascular stress [Kuba et al 2007; Charo et 
al 2009]. However expression of the apelin system is reduced in both animal models 
of heart failure [Iwanaga et al 2006; Jia et al 2006] and patients with chronic heart 
failure [Földes et al 2003; Chong et al 2006], and this down regulation appears to 
parallel the deterioration in cardiac performance. The down regulation of the apelin 
system in heart failure may therefore exacerbate myocardial dysfunction and 
represent a further maladaptive neurohormonal response in addition to over-
stimulation of the renin-angiotensin-aldosterone and adrenergic systems. 
Importantly, the beneficial effects of exogenous apelin on cardiac contractility and 
loading conditions are maintained in preclinical models of heart failure [Berry et al 
2004; Atluri et al 2007; Farkasfalvi et al 2007]. This confirms that, irrespective of 
changes in apelin system expression, the signalling capacity of the apelin receptor is 
not exhausted by endogenous apelin and provides a powerful rationale for exploring 
the therapeutic potential of apelin receptor agonism in patients with heart failure.   
 
To date, the cardiovascular effects of apelin receptor agonism in vivo in man have 
not been established and the therapeutic potential of this strategy cannot be realised 
without detailed clinical investigation. Through a series of clinical studies combing 
local and regional infusions of two apelin peptides with robust and well-validated 
techniques, I have addressed this important research priority. Specifically, I have 
established the in vivo effects of apelin receptor agonism in man on venous and 
peripheral resistance vessel tone, coronary blood flow and cardiac and systemic 
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haemodynamics. Additionally I have compared the direct vascular and systemic 
haemodynamic effects of the two principal biologically active apelin receptor ligands 
in man and examined the endothelial mechanisms by which apelin evokes its direct 
vascular actions. Having demonstrated these effects in healthy volunteers I have then 
examined cardiovascular responses to apelin receptor agonism in patients with 
chronic heart failure and compared these to age- and sex-matched healthy controls.  
 
7.2 THE DIRECT VASCULAR ACTIONS OF APELIN IN VIVO IN MAN 
 
Ex vivo, apelin causes endothelium-dependent vasorelaxation in human mesenteric 
artery [Salcedo et al 2007] and direct vasconstriction in endothelium-denuded human 
saphenous vein and mammary artery [Katugampola et al 2001; Maguire et al 2009]. 
In rodent models, in vivo, the predominant vascular effect is vasodilatation in the 
arterial and venous circulation [Tatemoto et al 2001; Cheng et al 2003]. In this thesis 
I have for the first time explored the in vivo effects of apelin in the human 
vasculature. Specifically, I sought to determine its direct vasomotor effects in the 
peripheral venous and peripheral and coronary arterial circulation. 
 
Local infusion of apelin-36 or (Pyr1)apelin-13 had no effect on either basal or 
preconstricted dorsal hand vein diameter suggesting that apelin does not modulate 
peripheral venous tone in vivo in man. However superficial skin veins are not 
representative of other venous beds and are of less haemodynamic importance than 
deep capacitance veins [Schmitt et al 2002]. During subsequent invasive studies, I 
observed a reduction in LVEDP following apelin administration. This finding is 
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consistent with preclinical data in rodents and provides indirect evidence that apelin 
acts as a venodilator, effecting a net reduction in systemic venous tone.  
 
In contrast to the lack of effect in hand veins, I have demonstrated that apelin causes 
reproducible and sustained vasodilation in the human arterial forearm circulation. 
The vasodilator response to apelin exhibited a rapid onset and a slow offset with 
effects persisting for up to 42 minutes after cessation of infusion. By measuring local 
plasma apelin concentrations, I was able to confirm that this effect was not due to 
persistence of circulating apelin. Whilst some in vitro responses to apelin exhibit 
desensitisation, forearm vasodilatation was sustained with no evidence of 
tachyphylaxis during a continuous 42-minute infusion.  
 
Having established the vasoactive effects of apelin in the human forearm circulation, 
I next sought to determine the contribution of the endothelium-derived vasodilators 
nitric oxide and prostacyclin to apelin-mediated vasodilatation. Utilising the nitric 
oxide clamp, I have demonstrated that apelin-mediated vasodilatation in vivo is 
mediated predominantly through nitric oxide. In contrast there was no discernible 
contribution from prostacyclin generation. This is in keeping with myography studies 
in human mesenteric artery where apelin-mediated vasorelaxation was attenuated by 
nitric oxide synthase but not cyclooxygenase inhibition [Salcedo et al 2007]. 
Recently apelin has been reported to cause prostacyclin-dependent vasorelaxation    
ex vivo in human mammary artery from patients undergoing coronary artery bypass 
surgery [Maguire et al 2009]. Further work is therefore required to determine 
whether prostacyclin contributes to apelin-mediated vasodilatation in vivo in subjects 
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with established endothelial dysfunction. Although apelin is capable of inducing 
vasoconstriction in endothelium-denuded vessels in vitro through a direct effect on 
vascular smooth muscle, there are no reports of vasoconstriction in vivo. 
Correspondingly, I have demonstrated that in the healthy human vasculature, the 
predominant vascular effect of apelin in vivo is vasodilatation even in the presence of 
combined prostacyclin and nitric oxide inhibition.  
 
Establishing the in vivo effects of apelin on coronary blood flow is critical to 
determining the potential therapeutic application of apelin receptor agonism. 
Consistent with its effects in the forearm arterial circulation, I have demonstrated 
that apelin is a direct coronary vasodilator in man. Apelin has recently been reported 
to cause vasoconstriction in vitro in human atherosclerotic coronary artery         
[Pitkin et al 2010b]. The patients in my studies were free of significant coronary 
artery disease and hence the in vivo vasomotor effects of apelin on atherosclerotic 
coronary arteries have yet to be established.  
 
7.3 THE CARDIAC AND SYSTEMIC HAEMODYNAMIC EFFECTS OF 
APELIN IN MAN  
 
In keeping with findings in preclinical models, I have shown that apelin 
administration in man increases cardiac contractility and output. The concomitant 
reduction in peripheral vascular resistance and transient rise in heart rate during 
intravenous apelin infusion suggest that this effect is mediated, at least in part, by 
reduced afterload and reflex sympathetic activation secondary to arterial 
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vasodilatation. However an additional direct myocardial action is suggested by the 
potent inotropic effects of apelin in human cardiac tissue ex vivo. Consistent with 
this, I have demonstrated an increase in left ventricular dP/dtmax following 
intracoronary apelin injection. However, dP/dtmax is sensitive to ventricular loading 
conditions which, in these studies, were also altered indicating likely spillover of 
apelin from the coronary circulation into the peripheral circulation and consequent 
systemic vascular effects. Therefore this thesis does not provide definitive evidence 
of a direct effect of apelin on myocardial contractility in vivo in man.    
 
In accordance with preclinical data and my findings in the forearm arterial 
circulation, systemic apelin administration reduces peripheral vascular resistance 
and, in older adults, causes a transient reduction in mean arterial pressure. Moreover, 
intracoronary administration reduces left ventricular end-diastolic and peak pressure. 
These results demonstrate, for the first time, that the direct vascular actions of apelin 
in man translate into alterations in systemic haemodynamics and left ventricular 
loading conditions and provide the first evidence of apelin-mediated vasodilatation in 
the human venous circulation. 
 
7.4 CARDIOVASCULAR RESPONSES TO APELIN IN PATIENTS WITH 
CHRONIC HEART FAILURE 
 
The demonstration in Chapters 3-5 of this thesis that exogenous apelin 
administration in man causes peripheral and coronary arterial vasodilatation, 
augments cardiac contractility and output and reduces left ventricular preload and 
 151 
afterload suggested potential therapeutic application in heart failure. Accordingly, I 
sought to determine cardiovascular responses to apelin receptor agonism in patients 
with stable chronic heart failure and to compare these with age- and sex-matched 
controls. Consistent with preclinical findings in vitro and in vivo, I have shown that 
the direct vascular and systemic haemodynamic effects of acute apelin administration 
are maintained in this patient population. In both patients and controls, intrabrachial 
apelin infusion increased FBF whist systemic intravenous infusion increased cardiac 
output and reduced peripheral vascular resistance. Heart rate increased transiently in 
controls but not patients. In both groups there was a small reduction in blood 
pressure but this appeared to be more sustained in the patient group.  
 
Patients with advanced chronic heart failure exhibit an apparent down regulation of 
the apelin system that parallels findings in preclinical models and includes reduced 
cardiac expression of the apelin receptor [Földes et al 2003; Chong et al 2006]. 
Importantly, these patients were maintained on current optimal pharmacological 
therapy, suggesting that the effects of apelin were additive to established heart failure 
treatments. In particular, all but one of the patients were receiving treatment with an 
ACE inhibitor or angiotensin receptor blocker therapy. Recent reports of direct 
interactions between the renin-angiotensin and apelin systems have raised the 
possibility that some of the actions of apelin may be mediated through antagonism of 
angiotensin II [Iwanaga et al 2006; Chun et al 2008]. However the findings in this 
thesis imply a role for apelin that is independent of angiotensin II signalling 
pathways, and suggest potential for pharmacological synergism through combined 
apelin receptor agonism and renin-angiotensin system inhibition. 
 152 
 
7.5 COMPARISON OF CARDIOVASCULAR RESPONSES TO 
DIFFERENT APELIN PEPTIDES  
 
The identity of the principal endogenous ligand for the apelin receptor in vivo 
remains uncertain. In this thesis I compared cardiovascular responses to apelin-36, 
the full-length mature peptide, with (Pyr1)apelin-13, recently shown to be the 
predominant isoform in human plasma and cardiac tissue. In the forearm vascular 
bed there was no difference in vasodilatation induced by the two apelin isoforms 
over a range of subsystemic doses. This is consistent with recent in vitro data 
showing that the same two peptides caused vasodilatation in human mammary artery 
with comparable potency [Maguire et al 2009]. Similarly, the magnitude of systemic 
haemodynamic responses to the two isoforms did not differ over the range of doses 
used in this study. This contrasts with the finding in rodents that shorter apelin 
fragments induce greater depressor effects than apelin-36 [Tatemoto et al 2001], 
suggesting possible interspecies differences in the responses to different apelin 
fragments. However, it may also reflect the greater interval between dosing and 
haemodynamic measurements in these studies as the differing responses in rodents 
were most apparent within the first 3 minutes after administration. 
 
I have demonstrated that both the direct vascular and systemic haemodynamic effects 
of apelin-36 have a more prolonged offset than the shorter isoform with 
vasodilatation persisting for at least 42 minutes after drug cessation. These findings 
mirror in vitro data showing rapid dissociation from the apelin receptor and transient 
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intracellular responses with (Pyr1)apelin-13 compared with much slower dissociation 
and prolonged receptor activation with apelin-36 [Hosoya et al 2000; Masri et al 
2006]. Such pharmacodynamic differences might potentially underpin distinct 
physiological roles for the different apelin isoforms in vivo. 
 
7.6 FUTURE DIRECTIONS  
 
7.6.1   APELIN ANTAGONISM 
Recently, Macaluso et al provided a report of the first small-molecule apelin 
antagonist, cyclo(1-6)CRPRLC-KH-cyclo(9-14)CRPRLC, demonstrating 
competitive inhibition of apelin-induced receptor internalisation and inhibition of 
cAMP production in cell lines transfected with the human apelin receptor [Macaluso 
et al 2011]. Pending confirmation of its efficacy, this agent could be used to 
characterise the cardiovascular actions of endogenous apelin both in preclinical 
models and clinical studies. 
 
In preclinical models, the vascular effects of exogenous apelin have been studied 
directly through wire myography [Salcedo et al 2007] and indirectly, in vivo, through 
changes in systemic blood pressure [Lee et al 2000, Tatemoto et al 2001], left 
ventricular filling pressures [Ashley et al 2005] and mean capillary filling pressure 
[Cheng et al 2003]. Additionally, the direct inotropic actions of exogenous apelin 
have been demonstrated in vitro, in single cardiomyocytes [Farkasfalvi et al 2007], 
paced atrial strips [Dai et al 2006; Maguire et al 2009] and Langendorff hearts 
[Szokodi et al 2002] and in vivo, by pressure-volume haemodynamics [Ashley et al 
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2005]. By combining these techniques with a selective apelin receptor antagonist, the 
role of endogenous apelin signalling in the regulation of cardiac contractility, and its 
contribution to the basal vascular tone could be established.  
 
Findings from murine models with deletion of the apelin or apelin receptor gene 
indicate a role for endogenous apelin signalling in preserving cardiac function during 
cardiovascular stress [Kuba et al 2007]. Correspondingly, the apelin system appears 
to be up regulated in the early stages of heart failure [Iwanaga et al 2006]. However, 
both expression of the apelin receptor and plasma apelin concentrations decline in 
advanced symptomatic disease [Iwanaga et al 2006; Jia et al 2006]. The 
pathophysiologic significance of changes in expression of the apelin pathway could 
be explored by examining the effects of apelin antagonism on cardiac function and 
systemic haemodynamics at different disease stages in animal models with                             
predictable progression to heart failure e.g. the Dahl salt-sensitive rat, correlating 
observed differences with changes in expression of apelin peptides and the apelin 
receptor.  
 
This thesis has characterised the acute cardiovascular effects of exogenous apelin in 
man. Owing to the lack of a validated apelin receptor antagonist at the time of the 
studies, I was unable to explore the role of endogenous apelin signalling in man. 
However, the techniques utilised in these studies could be readily applied to the 
study of apelin antagonism. Forearm venous occlusion plethysmography during 
continuous intrabrachial infusion of a putative apelin receptor antagonist or saline 
placebo with simultaneous graded infusions of apelin and control vasodilators could 
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be used to confirm its selective antagonism of the apelin receptor in man. Thereafter, 
the effects of the antagonist on forearm and coronary blood flow using the 
methodology described in Chapter 3 would reveal the contribution of endogenous 
apelin to the peripheral and coronary basal vascular tone in man. Intravenous 
infusions of an apelin antagonist combined with bioimpedance cardiography or 
pulmonary artery catheterisation could then be employed to establish the composite 
effects of endogenous apelin signalling on systemic haemodynamics. In these 
studies, simultaneous forearm venous occlusion plethysmography with locally active 
intrabrachial infusions of apelin receptor agonists would confirm the efficacy of the 
chosen systemic antagonist doses. Finally, potential alterations in endogenous apelin 
signalling in the setting of chronic heart failure, could be evaluated by determining 
the local vascular and systemic haemodynamic effects of apelin antagonism in 
patients with chronic heart failure using the methodology described in Chapter 6. 
 
7.6.2   THERAPEUTIC POTENTIAL OF CHRONIC APELIN RECEPTOR AGONISM 
The cardiovascular effects of acute apelin administration in rodents are now 
relatively well characterised but the impact of chronic administration requires further 
study. One of the most encouraging findings to date with apelin is the enhancement 
of cardiac performance with chronic administration that occurred without inducing 
left ventricular hypertrophy [Ashley et al 2005]. Further studies are required to 
confirm this finding over longer treatment periods and to clarify the effects, if any, of 
chronic apelin receptor agonism on cardiac expression of apelin receptors. 
Additionally the effects of chronic apelin administration in animal models of heart 
failure should be examined to determine the ability of apelin receptor agonism to 
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prevent or delay decline in cardiac function as well as to ameliorate the effects of 
established heart failure. 
 
In this thesis, I have assessed only the acute effects of apelin administration. The 
consequences of chronic apelin administration or agonism in patients with chronic 
heart failure cannot be inferred from these studies. Chronic dosing is not currently 
practicable or deliverable given the need for parenteral administration of apelin 
peptide. This problem could be addressed by the development of long-acting orally 
active apelin agonists or selective inhibitors of apelin degradation. However the 
enzymatic pathways responsible for inactivation of apelin peptides are presently 
unknown and, although the first non-peptidic apelin agonist, E339-3D6, has recently 
been described [Iturrioz et al 2010], to date, there are no reports of orally active 
apelin agonists. As an interim step, the effects of prolonged apelin infusion over a 
period of hours on cardiac contractility, systemic haemodynamics and fluid balance 
could be characterised. Confirmation of sustained arterial and venous dilatation, 
positive inotropy and diuretic effects over this time period would provide a rationale 
for a clinical trial to assess the therapeutic efficacy of intravenous apelin infusion in 
patients with acute decompensated heart failure. In addition to standard therapy with 
oxygen, diuretic and nitrates, patients presenting to the emergency department with 
acute pulmonary oedema could be randomised to a continuous 6-hour infusion of 
apelin or matched placebo. Appropriate endpoints could include improvement in 
arterial acidosis, breathlessness (visual analogue scale), neurohormonal markers, 




7.6.3   DIRECT CARDIAC EFFECTS OF APELIN IN VIVO 
Given the vasoactive actions of apelin described in this thesis, an assessment of its 
direct myocardial effects in vivo cannot be achieved using standard, load-dependent 
measures of contractility such as dP/dtmax or ejection fraction. To overcome this 
problem, the effects of apelin on load-independent indices of myocardial contractility 
could be studied using pressure-volume haemodynamics with the aid of a 
conductance catheter system e.g. CD Leycom CFL-512. This dedicated catheter 
system has a micromanometer to measure intraventricular pressures and sequential 
electrical impedance to measure ventricular volume. During intracoronary infusions 
of apelin or matched saline placebo, pressure changes within the left ventricle could 
be combined with volume data to form real-time pressure-volume loops over 
successive cardiac cycles, both at baseline and following manipulation of preload 
[Wittstein et al 2001]. In addition to standard measures of cardiac contractility and 
loading such as cardiac output, dP/dtmax, end-diastolic and end-systolic volumes and 
ejection fraction, this approach would permit measurement of end-systolic elastance 
(dP/dtmax/end-diastolic volume index) and end-systolic pressure-volume ratio as 
load-independent indices of systolic function [Kass and Maughan 1988]. Thus, 
effects of load and intrinsic contractility can be simultaneously and independently 
assessed. The same methodology combined with a validated apelin receptor 





7.6.4   APELIN AND VASCULAR DISEASE 
This thesis has demonstrated an increase in coronary blood flow following 
intracoronary apelin injection. However, the coronary vasomotor actions of apelin 
require further study. Graded infusions of apelin in place of two single intracoronary 
injections would permit more detailed characterisation of the time course and dose-
dependence of its effects. In addition, measurement of coronary artery cross-
sectional area with intravascular ultrasound might allow a more accurate assessment 
of epicardial vessel size than is achievable with QCA. Apelin potently constricts 
human atherosclerotic coronary artery. Paradoxical vasoconstriction of 
atherosclerotic coronary arteries has been described in vivo with other endothelium-
dependent vasodilators such as acetylcholine [Ludmer et al 1986] and this would 
have implications for the effects of apelin in patients with coronary artery disease. 
The direct coronary effects of apelin in patients with significant coronary artery 
disease and other conditions associated with endothelial dysfunction will therefore 
need to be examined.  
 
Apelin appears to have beneficial effects on vascular health. In diabetic mice, it 
increases vascular nitric oxide generation and reverses endothelial dysfunction 
[Zhong et al 2007]. The therapeutic potential of apelin receptor agonism in human 
vascular disease has yet to be explored. In this thesis I have demonstrated that apelin 
causes nitric oxide-mediated vasodilatation in vivo in forearm resistance vessels of 
healthy subjects but it is not yet known whether it reverses the endothelial 
dysfunction seen in pathophysiological states such as diabetes mellitus and 
hypercholesterolaemia. This question could be addressed by comparing vasodilator 
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responses to endothelium-dependent and -independent vasodilators in the forearm 
vascular bed of patients with these conditions following local intrabrachial infusion 
of apelin or saline placebo.  
 
Preclinical models and preliminary clinical data indicate that diminished apelin 
signalling may contribute to the pathogenesis of pulmonary hypertension [Alastalo et 
al 2011; Chandra et al 2011]. Furthermore, in line with findings in the systemic 
circulation, apelin causes nitric oxide-mediated vasorelaxation in pulmonary artery 
in vitro [Huang et al 2011] and a modest reduction in pulmonary artery pressure 
in vivo [Feng et al 2010]. The vasomotor effects of apelin in the pulmonary 
circulation have not been studied in man. This could be achieved by measurement of 
pulmonary haemodynamic indices with a pulmonary artery catheter during systemic 
intravenous infusions of apelin and matched saline placebo. Such a study would 
permit further examination of the effects of apelin on cardiac output and central 
filling pressures as well as pulmonary vascular resistance, the latter calculated by 
dividing the transpulmonary gradient by the cardiac output. After establishing the 
pulmonary haemodynamic effects of apelin in healthy volunteers, responses to apelin 
could be assessed in patients with idiopathic pulmonary arterial hypertension and 
pulmonary hypertension associated with left heart disease and compared with age- 
and sex-matched controls.  
 
7.6.5   INTERACTION OF THE APELIN AND RENIN-ANGIOTENSIN SYSTEMS 
The angiotensin II type 1 and apelin receptors exhibit close sequence homology and 
markedly similar patterns of tissue expression, yet apelin mediates opposing actions 
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to angiotensin II on vascular tone, blood pressure and fluid homeostasis [Ashley et al 
2006]. These findings suggest a counter-regulatory role for apelin in relation to the 
renin-angiotensin system, and recent preclinical data support this hypothesis. Apelin 
antagonises the proatherogenic effects of angiotensin II, and attenuates angiotensin 
II-mediated constriction of veins and arteries in rodent models [Guzru et al 2006; 
Chun et al 2008]. In contrast, mice with knockout of the apelin receptor gene exhibit 
an exaggerated pressor response to exogenous angiotensin II [Ishida et al 2004]. 
Given that apelin selectively inhibits angiotensin II-mediated transcription of 
multiple gene targets [Chun et al 2008], this regulation may occur, at least in part, 
through direct antagonism of angiotensin II signalling pathways.  
 
As shown in this thesis, local apelin infusion does not alter venous tone in the dorsal 
hand vein. Therefore, to determine whether apelin directly and selectively inhibits 
the acute vasomotor actions of angiotensin II in vivo in man, venoconstrictor 
responses to local intravenous infusions of angiotensin II and the control 
vasoconstricitor norepinephrine could be compared using the dorsal hand vein 
technique during co-infusion of apelin or saline placebo. To further explore the direct 
effects of apelin on vascular responses to angiotensin II, constrictor responses to 
intrabrachial angiotensin II and the control vasoconstricitor norepinephrine could be 
compared in the forearm circulation in the presence and absence of apelin or SNP 
(titrated to achieve equivalent baseline blood flow). By employing subsytemic doses 
of drugs in these studies, potentially confounding effects of angiotensin II and apelin 
on renal, endocrine and systemic haemodynamic factors will be avoided. In addition, 
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the control vasoconstrictor and vasodilator infusions will account for the non-specific 
vasomotor effects. 
 
There is also increasing evidence for direct counter-regulation of the apelin system 
by angiotensin II. In rats, infusion of angiotensin II for 24 hours, even at subpressor 
doses, reduces cardiac apelin expression, an effect abolished by concurrent AT1 
receptor blockade [Iwanaga et al 2006]. Similarly, in a rodent model of heart failure, 
several pharmacological treatments retard progression to chronic heart failure, but 
only AT1 receptor antagonism prevents down regulation of apelin and apelin receptor 
expression [Iwanaga et al 2006]. While basal blood pressure is normal in mice with 
selective knockout of the apelin receptor gene, it is elevated in mice with combined 
apelin and AT1 receptor knockout implying that, in the absence of angiotensin II 
activity, apelin contributes to basal vascular tone [Ishida et al 2004]. Finally 
angiotensin II has recently been shown to induce heterodimerisation of the apelin and 
AT1 receptors [Chun et al 2008], thereby providing a plausible mechanism for direct 
inhibition of apelin signalling by angiotensin II.  
 
To date there are no reports on the interactions between the apelin and renin-
angiotensin systems in man. Sodium depletion is a well-validated and 
physiologically relevant method of renin-angiotensin system stimulation and can be 
achieved through a low salt diet as previously described. This could be used as a 
model to study changes in plasma apelin concentrations and the direct vascular and 
systemic haemodynamic responses to exogenous apelin during sustained 
up regulation of endogenous angiotensin II production. Whilst this provides a valid 
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approach to assessing neurohumoral activation in healthy volunteers it must be 
acknowledged that sodium depletion will lead to alterations in other neurohormonal 
systems, such as the vasopressin system. Therefore, to establish whether the in vivo 
vasomotor effects of apelin in man are directly and selectively inhibited by 
concurrent AT1 receptor activation, FBF responses to intrabrachial infusion of apelin 
or the control endothelium-dependent vasodilator, acetylcholine, could be compared 
in the presence of angiotensin II or the control vasoconstrictor, norepinephrine. 
Similarly systemic haemodynamic responses to apelin could be compared during co-
infusion of angiotensin II at a subpressor dose such as 0.5 mg/kg/min [Ljungmanet et 
al 1983; Miller et al 1999] or saline placebo. Finally, following the development and 
validation of suitable antagonists of the apelin receptor these same protocols could be 
employed to assess the effects of differential states of renin-angiotensin system 
activation on endogenous apelin activity. 
 
7.7 CONCLUDING REMARKS 
 
Fourteen years since the pairing of the apelin receptor with its endogenous ligand, 
the field of apelin biology is, in many respects, still in its infancy. Whilst increasing 
data suggest an important role for the apelin system in cardiovascular physiology and 
pathophysiology, many fundamental aspects of the system have yet to be established. 
In particular, further work is required to elucidate the regulation of gene transcription 
and the degradation pathway of apelin peptides; to reconcile phenotypic differences 
between receptor and ligand knockout models; to clarify intracellular signalling 
mechanisms; and to develop new pharmacological tools such as selective antagonists 
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and long-acting agonists to explore the physiological relevance of the apelin 
signalling. Advances in these areas will serve to inform and complement studies such 
as those described and others designed to clarify the physiological role and 
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